MannKind (MNKD) 10-Q 7 Aug 23 2023 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Jul. 28, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Trading Symbol	MNKD
Entity Registrant Name	MannKind Corporation
Entity Central Index Key	0000899460
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity File Number	000-50865
Entity Tax Identification Number	13-3607736
Entity Address, Address Line One	1 Casper Street
Entity Address, City or Town	Danbury
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06810
City Area Code	818
Local Phone Number	661-5000
Entity Common Stock, Shares Outstanding		268,355,182
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenues:
Total revenues	$ 48,611	$ 18,894	$ 89,237	$ 30,886
Expenses:
Cost of goods sold	5,224	4,617	10,754	6,901
Research and development	6,453	4,893	12,058	8,429
Selling	14,002	15,868	27,312	28,596
General and administrative	11,947	10,175	22,489	18,144
Loss (gain) on foreign currency transaction	251	(4,503)	1,205	(6,486)
Total expenses	46,890	39,348	93,514	72,596
Income (loss) from operations	1,721	(20,454)	(4,277)	(41,710)
Other income (expense):
Interest income, net	1,547	516	2,849	893
Interest expense on financing liability	(2,449)	(2,443)	(4,873)	(4,814)
Interest expense	(6,873)	(6,642)	(9,659)	(9,390)
Gain on available-for-sale securities	932		932
Other expense	(143)		(32)
Total other expense	(6,986)	(8,569)	(10,783)	(13,311)
Loss before income tax expense	(5,265)	(29,023)	(15,060)	(55,021)
Benefit from income taxes	0	0	0	0
Net loss	$ (5,265)	$ (29,023)	$ (15,060)	$ (55,021)
Net loss per share - basic	$ (0.02)	$ (0.11)	$ (0.06)	$ (0.22)
Net loss per share - diluted	$ (0.02)	$ (0.11)	$ (0.06)	$ (0.22)
Weighted average shares used to compute net loss per share - basic	265,626	253,644	264,802	252,775
Weighted average shares used to compute net loss per share - diluted	265,626	253,644	264,802	252,775
Commercial product sales
Revenues:
Total revenues	$ 18,345	$ 12,722	$ 35,907	$ 22,548
Collaborations and services
Revenues:
Total revenues	11,211	5,868	22,597	8,034
Expenses:
Cost of revenue	9,013	8,298	19,696	17,012
Royalties collaborations
Revenues:
Total revenues	$ 19,055	$ 304	$ 30,733	$ 304

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of Comprehensive Income [Abstract]
Net Income (Loss)	$ (5,265)	$ (29,023)	$ (15,060)	$ (55,021)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities	443	(130)	443	(1,206)
Comprehensive loss	$ (4,822)	$ (29,153)	$ (14,617)	$ (56,227)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 86,184	$ 69,767
Short-term investments	58,163	101,079
Accounts receivable, net	27,789	16,801
Inventory	25,290	21,772
Prepaid expenses and other current assets	32,807	25,477
Total current assets	230,233	234,896
Property and equipment, net	69,510	45,126
Goodwill	1,931	2,428
Other intangible asset	1,113	1,153
Long-term investments	2,282	1,961
Other assets	8,353	9,718
Total assets	313,422	295,282
Current liabilities:
Accounts payable	17,127	11,052
Accrued expenses and other current liabilities	36,833	35,553
Financing liability — current	9,686	9,565
Midcap credit facility - current	16,667
Deferred revenue — current	3,489	1,733
Recognized loss on purchase commitments — current	13,164	9,393
Total current liabilities	96,966	67,296
Mann Group convertible note	8,829	8,829
Accrued interest - Mann Group convertible note	55	55
Financing liability — long term	94,395	94,512
Midcap credit facility - long term	22,811	39,264
Senior convertible notes	226,124	225,397
Recognized loss on purchase commitments — long term	56,063	62,916
Operating lease liability	4,646	5,343
Deferred revenue — long term	60,248	37,684
Milestone liabilities	3,772	4,524
Total liabilities	573,909	545,820
Commitments and contingencies (Note 15)
Stockholders' deficit:
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding as of June 30, 2023 and December 31, 2022
Common stock, $0.01 par value - 800,000,000 and 400,000,000 shares authorized as of June 30, 2023 and December 31, 2022, respectively, and 268,235,145 and 263,793,305 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	2,682	2,638
Additional paid-in capital	2,968,917	2,964,293
Accumulated other comprehensive income	443
Accumulated deficit	(3,232,529)	(3,217,469)
Total stockholders' deficit	(260,487)	(250,538)
Total liabilities and stockholders' deficit	$ 313,422	$ 295,282

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Undesignated preferred stock, par value	$ 0.01	$ 0.01
Undesignated preferred stock, shares authorized	10,000,000	10,000,000
Undesignated preferred stock, shares issued	0	0
Undesignated preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	800,000,000	400,000,000
Common stock, shares issued	268,235,145	263,793,305
Common stock, shares outstanding	268,235,145	263,793,305

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands	Total	Convertible Note The Mann Group L L C	Convertible Note Interest The Mann Group L L C	At-the-market Placement	Common Stock	Common Stock Convertible Note The Mann Group L L C	Common Stock Convertible Note Interest The Mann Group L L C	Common Stock At-the-market Placement	Additional Paid-in Capital	Additional Paid-in Capital Convertible Note The Mann Group L L C	Additional Paid-in Capital Convertible Note Interest The Mann Group L L C	Additional Paid-in Capital At-the-market Placement	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning Balance at Dec. 31, 2021	$ (209,349)				$ 2,515				$ 2,918,205					$ (3,130,069)
Beginning Balance (in shares) at Dec. 31, 2021					251,478
Net issuance of common stock associated with stock options and restricted stock units	129				$ 4				125
Net issuance of common stock associated with stock options and restricted stock units (in shares)					450
Issuance of common stock under the employee stock purchase plan	740				$ 2				738
Issuance of common stock under the employee stock purchase plan (in shares)					233
Stock-based compensation expense	2,806								2,806
Issuance of common stock from market price stock purchase plan	684				$ 3				681
Issuance of common stock from Market Price Stock Purchase Plan (in shares)					252
Cumulative gain (loss) on available-for-sale securities	(1,076)												$ (1,076)
Net Income (Loss)	(25,998)													(25,998)
Ending Balance at Mar. 31, 2022	(232,064)				$ 2,524				2,922,555				(1,076)	(3,156,067)
Ending Balance (in shares) at Mar. 31, 2022					252,413
Beginning Balance at Dec. 31, 2021	(209,349)				$ 2,515				2,918,205					(3,130,069)
Beginning Balance (in shares) at Dec. 31, 2021					251,478
Net Income (Loss)	(55,021)
Ending Balance at Jun. 30, 2022	(247,056)				$ 2,573				2,936,667				(1,206)	(3,185,090)
Ending Balance (in shares) at Jun. 30, 2022					257,277
Beginning Balance at Mar. 31, 2022	(232,064)				$ 2,524				2,922,555				(1,076)	(3,156,067)
Beginning Balance (in shares) at Mar. 31, 2022					252,413
Net issuance of common stock associated with stock options and restricted stock units	(377)				$ 8				(385)
Net issuance of common stock associated with stock options and restricted stock units (in shares)					833
Stock-based compensation expense	4,422								4,422
Issuance of common stock pursuant to conversion notes		$ 9,596	$ 520			$ 39	$ 2			$ 9,557	$ 518
Issuance of common stock pursuant to conversion notes (in shares)						3,838	193
Cumulative gain (loss) on available-for-sale securities	(130)												(130)
Net Income (Loss)	(29,023)													(29,023)
Ending Balance at Jun. 30, 2022	(247,056)				$ 2,573				2,936,667				(1,206)	(3,185,090)
Ending Balance (in shares) at Jun. 30, 2022					257,277
Beginning Balance at Dec. 31, 2022	(250,538)				$ 2,638				2,964,293					(3,217,469)
Beginning Balance (in shares) at Dec. 31, 2022					263,793
Net issuance of common stock associated with stock options and restricted stock units	52				$ 2				50
Net issuance of common stock associated with stock options and restricted stock units (in shares)					206
Stock-based compensation expense	3,655								3,655
Issuance of common stock pursuant to conversion notes			55								55
Issuance of common stock pursuant to conversion notes (in shares)							11
Issuance of common stock associated with at-the-market placement				$ 1,199				$ 3				$ 1,196
Issuance of common stock associated with at-the-market placement (in shares)								269
Issuance costs associated with at-the- market placement	(24)								(24)
Net Income (Loss)	(9,795)													(9,795)
Ending Balance at Mar. 31, 2023	(255,396)				$ 2,643				2,969,225					(3,227,264)
Ending Balance (in shares) at Mar. 31, 2023					264,279
Beginning Balance at Dec. 31, 2022	(250,538)				$ 2,638				2,964,293					(3,217,469)
Beginning Balance (in shares) at Dec. 31, 2022					263,793
Net Income (Loss)	(15,060)
Ending Balance at Jun. 30, 2023	(260,487)				$ 2,682				2,968,917				443	(3,232,529)
Ending Balance (in shares) at Jun. 30, 2023					268,235
Beginning Balance at Mar. 31, 2023	(255,396)				$ 2,643				2,969,225					(3,227,264)
Beginning Balance (in shares) at Mar. 31, 2023					264,279
Net issuance of common stock associated with stock options and restricted stock units	(8,544)				$ 32				(8,576)
Net issuance of common stock associated with stock options and restricted stock units (in shares)					3,279
Issuance of common stock under the employee stock purchase plan	923				$ 3				920
Issuance of common stock under the employee stock purchase plan (in shares)					266
Stock-based compensation expense	5,580								5,580
Issuance of common stock pursuant to conversion notes			$ 54								$ 54
Issuance of common stock pursuant to conversion notes (in shares)							13
Issuance of common stock from market price stock purchase plan	152								152
Issuance of common stock from Market Price Stock Purchase Plan (in shares)					36
Cumulative gain (loss) on available-for-sale securities	443												443
Issuance of common stock associated with at-the-market placement				$ 1,583				$ 4				$ 1,579
Issuance of common stock associated with at-the-market placement (in shares)								362
Issuance costs associated with at-the- market placement	(17)								(17)
Net Income (Loss)	(5,265)													(5,265)
Ending Balance at Jun. 30, 2023	$ (260,487)				$ 2,682				$ 2,968,917				$ 443	$ (3,232,529)
Ending Balance (in shares) at Jun. 30, 2023					268,235

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (15,060)	$ (55,021)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	9,235	7,228
Interest expense on financing liability	4,873	4,814
Write-off of inventory	3,359	451
Depreciation and amortization	2,173	1,326
Loss (gain) on foreign currency transaction	1,205	(6,486)
Amortization of debt discount and issuance costs	941	940
Amortization of right-of-use assets	657	2,331
Gain on available-for-sale securities	(932)
Other, net	(245)	469
Interest on milestone right		3,912
Changes in operating assets and liabilities:
Accounts receivable, net	(10,988)	(10,036)
Inventory	(6,877)	(2,720)
Prepaid expenses and other current assets	(5,231)	(235)
Other assets	(20)	(441)
Accounts payable	6,075	867
Accrued expenses and other current liabilities	(4,403)	(134)
Deferred revenue	24,320	11,059
Recognized loss on purchase commitments	(4,286)	(2,928)
Operating lease liabilities	(1,153)	(2,441)
Deposits from customer		(3,387)
Net cash provided by (used in) operating activities	3,752	(50,230)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from maturity of debt securities	69,083	53,307
Purchase of held-to-maturity debt securities	(26,447)	(68,470)
Purchase of property and equipment	(25,180)	(2,222)
Acquisition of V-Go		(15,099)
Purchase of available-for-sale securities		(5,000)
Net cash provided by (used in) investing activities	17,456	(37,484)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from market price stock purchase plan and employee stock purchase plan	1,075	684
Payments for taxes related to net issuance of common stock associated with restricted stock units and stock options	(8,492)	(248)
Payment on financing liability	(115)	(1,399)
Net cash used in financing activities	(4,791)	(963)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	16,417	(88,677)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	69,767	124,184
CASH AND CASH EQUIVALENTS, END OF PERIOD	86,184	35,507
SUPPLEMENTAL CASH FLOWS DISCLOSURES:
Interest paid in cash	4,259	4,341
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Reclassification of Midcap credit facility from long-term to current	16,667
Reclassification of investments from long-term to current	2,623	52,236
Non-cash construction in progress, property and equipment	1,858	916
Right-of-use asset modification	728	3,794
Goodwill adjustment for a net reduction in liabilities	497
Payments on debt and interest through common stock issuance	109	10,116
Issuance of common stock under employee stock purchase plan		740
Addition of right-of-use-asset		1,812
UT owned property and equipment		1,563
Contingent milestone liability		610
The Mann Group L L C
Adjustments to reconcile net loss to net cash used in operating activities:
Interest expense on Mann Group convertible note	109	$ 202
At The Market Issuance
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from at-the-market offering	2,782
Issuance costs associated with at-the-market offering	$ (41)

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ (5,265)	$ (9,795)	$ (29,023)	$ (25,998)	$ (15,060)	$ (55,021)

Insider Trading Arrangements

Insider Trading Arrangements	6 Months Ended
	Jun. 30, 2023 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	During the three months ended June 30, 2023, one of our executive officers adopted a written trading plan for the orderly disposition of the Company’s securities as set forth in the table below: Type of Trading Arrangement Name and Position Action Date Rule (1) Non-Rule (2) Total Shares of Common Stock to be Sold Expiration Date Stuart A. Tross , EVP Chief People and Workplace Officer Adoption May 24, 2023 X — 384,020 May 24, 2024 _________________________ (1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. (2) "Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.
Name	Stuart A. Tross
Title	EVPChief People and Workplace Officer
Rule 10b5-1 Arrangement Adopted	true
Non-Rule 10b5-1 Arrangement Adopted	false
Adoption Date	May 24, 2023
Aggregate Available	384,020

Description of Business and Sig

Description of Business and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Description of Business and Significant Accounting Policies	1. Description of Business and Significant Accounting Policies The unaudited condensed consolidated financial statements of MannKind Corporation and its subsidiaries (“MannKind,” the “Company,” “we” or “us”), have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on February 23, 2023 (the “Annual Report”). In the opinion of management, all adjustments, consisting only of normal, recurring adjustments, considered necessary for a fair presentation of the results of these interim periods have been included. The results of operations for the three and six months ended June 30, 2023 may not be indicative of the results that may be expected for the full year. Financial Statement Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates or assumptions. Management considers many factors in selecting appropriate financial accounting policies, and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The more significant estimates include revenue recognition, including gross-to-net adjustments, stand-alone selling price considerations for recognition of collaboration revenue, assessing long-lived assets for impairment, clinical trial expenses, inventory costing and recoverability, recognized loss on purchase commitment, milestone rights liability, stock-based compensation and the determination of the provision for income taxes and corresponding deferred tax assets and liabilities, and the valuation allowance recorded against net deferred tax assets. Business — MannKind is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The Company’s signature technologies, Technosphere dry-powder formulations and Dreamboat inhalation devices, offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. The Company is currently commercializing Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. The first product to come out of the orphan lung disease pipeline, Tyvaso DPI (treprostinil) inhalation powder, received approval from the U.S. Food and Drug Administration (“FDA”) in May 2022 for the treatment of pulmonary arterial hypertension (PAH) and for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company's development and marketing partner, United Therapeutics ("UT") began commercializing Tyvaso DPI in June 2022 and is obligated to pay the Company a royalty on net sales of the product. The Company also receives a margin on supplies of Tyvaso DPI that it manufactures for UT. Basis of Presentation — The condensed consolidated financial statements have been prepared in accordance with GAAP. Principles of Consolidation — The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated. Reclassifications — Certain prior year reported amounts have been reclassified to conform with the current year presentation. Changes were made to the condensed consolidated statements of cash flows to present the amortization of debt discount and issuance costs separately and to disclose net investment accretion under other, net. In addition, changes were made to the condensed consolidated statements of operations to present selling expenses separately from general and administrative expenses. Segment Information — Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as one segment operating in the United States of America. Revenue Recognition — The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC 606, including when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company has two types of contracts with customers: (i) contracts for commercial product sales with wholesale distributors, specialty and retail pharmacies and (ii) collaboration arrangements. Revenue Recognition — Net Revenue – Commercial Product Sales — The Company sells its products to a limited number of wholesale distributors, specialty and retail pharmacies, and durable medical equipment suppliers (“DME”) in the U.S. (collectively, its “Customers”). Wholesale distributors subsequently resell the Company’s products to retail pharmacies and certain medical centers or hospitals. Specialty and retail pharmacies sell directly to patients. In addition to distribution agreements with Customers, the Company enters into arrangements with payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenue on product sales when the Customer obtains control of the Company's product, which occurs at delivery for wholesale distributors and generally at delivery for specialty pharmacies. The Company recognizes revenue on product sales to a retail pharmacy as the product is dispensed to patients. Product revenues are recorded net of applicable reserves, including discounts, allowances, rebates, returns and other incentives. See Reserves for Variable Consideration below. Free Goods Program — From time to time, the Company offers programs to potential new patients that allow them to obtain free goods (prescription fills) from a pharmacy. The Company excludes such amounts related to these programs from both gross and net revenue. The cost of product associated with the free goods program is recognized as cost of goods sold in the condensed consolidated statements of operations. Reserves for Variable Consideration — Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its Customers, payers, and other indirect customers relating to the Company’s sale of its products. These reserves, as further detailed below, are based on the amounts earned, or to be claimed on the related sales, and result in a reduction of accounts receivable or establishment of a current liability. Significant judgment is required in estimating gross-to-net adjustments, including historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, claim submission time lags and inventory levels in the distribution channel. Where appropriate, these estimates take into consideration a range of possible outcomes, which are probability-weighted in accordance with the expected value method in ASC 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reduce recognized revenue to the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analysis also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the current period estimates of gross-to-net adjustments and, therefore, the transaction price was not reduced further during the current period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net revenue from commercial product sales and earnings in the period such variances become known. Trade Discounts and Allowances — The Company generally provides Customers with discounts which include incentives, such as prompt pay discounts, that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its Customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company’s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of revenue and as a reduction to accounts receivable, net. Product Returns — Consistent with industry practice, the Company generally offers Customers a right of return for unopened product that has been purchased from the Company for a period beginning six months prior to and ending 12 months after its expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as reductions to accounts receivable, net. The Company currently estimates product returns using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company’s current return reserve percentage is estimated to be in the single digits. Adjustments to the returns reserve have been made in the past and may be necessary in the future based on revised estimates to the Company’s assumptions. Provider Chargebacks and Discounts — Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase products from the Company. Customers charge the Company for the difference between what they pay for products and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is recorded in accrued expenses and other current liabilities. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by Customers, and the Company generally issues credits for such amounts within a few weeks of the Customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, and chargebacks that Customers have claimed, but for which the Company has not yet issued a credit. Government Rebates — The Company is subject to discount obligations under Medicare and state Medicaid programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses and other current liabilities. Estimates around Medicaid have historically required significant judgment due to timing lags in receiving invoices for claims from states. For Afrezza, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for products that have been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. The Company’s estimates include consideration of historical claims experience, payer channel mix, current contract prices, unbilled claims, claim submission time lags and inventory in the distribution channel. Payer Rebates — The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates, including estimates for product that has been recognized as revenue, but which remains in the distribution channel, and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities. The Company’s estimates include consideration of historical claims experience, payer channel mix, current contract prices, unbilled claims, claim submission time lags and inventory in the distribution channel. Other Incentives — Other incentives which the Company offers include voluntary patient support programs, such as the Company's co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with co-payments required by payers. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with the products that have been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses and other current liabilities. Revenue Recognition — Revenue – Collaborations and Services — The Company enters into licensing, research or other agreements under which the Company licenses certain rights to its product candidates to third parties, conducts research or provides other services to third parties. The terms of these arrangements may include but are not limited to payment to the Company of one or more of the following: up-front license fees; development, regulatory, and commercial milestone payments; payments for commercial manufacturing and clinical supply services the Company provides; and royalties on net sales of licensed products and sublicenses of the rights. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment such as determining the performance obligation in the contract and determining the stand-alone selling price for each performance obligation identified in the contract. With respect to the Company's significant collaboration and service agreement with UT that includes a long-term commercial supply agreement (as amended, the “CSA”), the Company has identified three distinct performance obligations: (1) the license, supply of product to be used in clinical development, and continued development and approval support for Tyvaso DPI (“R&D Services and License”); (2) development activities for the next generation of the product (“Next-Gen R&D Services”); and (3) a material right associated with current and future manufacturing and supply of product (“Manufacturing Services”). Pre-production activities under the CSA, such as facility expansion services and other administrative services, were considered bundled services under the Manufacturing Services performance obligation as required by ASC 606. Following the FDA’s approval of Tyvaso DPI, UT began issuing purchase orders for the supply of product, which represents distinct contracts and performance obligations under ASC 606. Revenue is recognized for the supply of product at a point in time, once control is transferred to UT. See Note 10 – Collaboration, Licensing and Other Arrangements. If an arrangement has multiple performance obligations, the allocation of the transaction price is determined from observable market inputs, and the Company uses key assumptions to determine the stand-alone selling price, which may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success. Revenue is recognized based on the measurement of progress as the performance obligation is satisfied and consideration received that does not meet the requirements to satisfy the revenue recognition criteria is recorded as deferred revenue. Current deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. For further information, see Note 10 – Collaboration, Licensing and Other Arrangements. The Company recognizes upfront license payments as revenue upon delivery of the license only if the license is determined to be a separate unit of accounting from the other undelivered performance obligations. The undelivered performance obligations typically include manufacturing or development services or research and/or steering committee services. If the license is not considered as a distinct performance obligation, then the license and other undelivered performance obligations would be evaluated to determine if such should be accounted for as a single unit of accounting. If concluded to be a single performance obligation, the transaction price for the single performance obligation is recognized as revenue over the estimated period of when the performance obligation is satisfied. If the license is considered to be a distinct performance obligation, then the estimated revenue is included in the transaction price for the contract, which is then allocated to each performance obligation based on the respective standalone selling prices. Whenever the Company determines that an arrangement should be accounted for over time, the Company determines the period over which the performance obligations will be performed, and revenue will be recognized over the period the Company is expected to complete its performance obligations. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. The Company’s collaboration agreements typically entitle the Company to additional payments upon the achievement of development, regulatory and sales milestones. If the achievement of a milestone is considered probable at the inception of the collaboration, the related milestone payment is included with other collaboration consideration, such as upfront fees and research funding, in the Company’s revenue calculation. If these milestones are not considered probable at the inception of the collaboration, the milestones will typically be recognized in one of two ways depending on the timing of when the milestone is achieved. If the milestone is improbable at inception and subsequently deemed probable of achievement, such will be added to the transaction price, resulting in a cumulative adjustment to revenue. If the milestone is achieved after the performance period has been completed and all performance obligations have been delivered, the Company will recognize the milestone payment as revenue in its entirety in the period the milestone was achieved. The Company’s collaborative agreements, for accounting purposes, represent contracts with customers and therefore are not subject to accounting literature on collaborative agreements. The Company grants licenses to its intellectual property, supplies raw materials, semi-finished goods or finished goods, provides research and development services and offers sales support for the co-promotion of products, all of which are outputs of the Company’s ongoing activities, in exchange for consideration. Accordingly, the Company concluded that its collaborative agreements must generally be accounted for pursuant to ASC 606. For collaboration agreements that allow collaboration partners to select additional optioned products or services, the Company evaluates whether such options contain material rights (i.e., have exercise prices that are discounted compared to what the Company would charge for a similar product or service to a new collaboration partner). The exercise price of these options includes a combination of licensing fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, the Company concludes the option does not contain a material right, and therefore is not included in the transaction price at contract inception. The Company assessed the CSA agreement with UT and determined that a material right existed for the manufacturing services performance obligation. The transaction price is allocated to the material right as well as the remaining performance obligations in accordance with ASC 606. The Company also evaluates grants of additional licensing rights upon option exercises to determine whether such should be accounted for as separate contracts. Revenue Recognition – Royalties — The Company recognizes royalty revenue for a sales-based or usage-based royalty if it is promised in exchange for an intellectual property license. The royalty revenue is recognized as the latter of the subsequent sale of the product occurs or if the performance obligation to which the royalty has been allocated has been satisfied or partially satisfied. The Company’s collaborative agreement with UT entitles it to receive low double-digit royalties on net sales of Tyvaso DPI for the license of the Company’s IP that was considered to be interdependent with the development activities that supported the approval of Tyvaso DPI. The Company’s net revenue and cost of revenue and goods sold as shown on the condensed consolidated statement of operations is comprised of revenue generated from product sales, services and royalties as shown below (in thousands): Three Months Six Months 2023 2022 2023 2022 Net revenue: Product sales (1) $ 29,278 $ 17,417 $ 58,004 $ 28,427 Services (2) 278 1,173 500 2,155 Royalties (3) 19,055 304 30,733 304 Total net revenue $ 48,611 $ 18,894 $ 89,237 $ 30,886 _________________________ (1) Amounts represent the net sales of Afrezza and V-Go to wholesalers and specialty pharmacies and Tyvaso DPI to UT. (2) Amounts represent revenue generated from the Company's collaboration arrangements, including Next-Gen R&D Services (as defined in Note 10) for UT as well as arrangements with other collaboration partners. See Note 10 – Collaboration, Licensing and Other Arrangements . (3) Amounts represent royalties on UT’s net sales of Tyvaso DPI. Three Months Six Months 2023 2022 2023 2022 Cost of goods sold and cost of revenue: Product sales $ 13,995 $ 12,481 $ 30,023 $ 22,967 Services 242 434 427 946 Total cost of goods sold and cost of revenue $ 14,237 $ 12,915 $ 30,450 $ 23,913 The Company follows detailed accounting guidance in measuring revenue and certain judgments affect the application of its revenue policy. For example, in connection with its existing collaboration agreements, the Company has recorded on its condensed consolidated balance sheets short-term and long-term deferred revenue based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. However, this estimate is based on the Company’s current project development plan and, if the development plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12 -month period. Milestone Payments — At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the customer, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as, or when, the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration, other revenue, and earnings in the period of adjustment. Cost of Goods Sold — Cost of goods sold includes material, labor costs and manufacturing overhead. Cost of goods sold also includes a component of current period manufacturing costs in excess of costs capitalized into inventory (“excess capacity costs”). These costs, in addition to the impact of the revaluation of inventory for standard costing, and write-offs of inventory are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. Cost of goods sold excludes the cost of insulin purchased under the Company’s Insulin Supply Agreement (the “Insulin Supply Agreement”) with Amphastar Pharmaceuticals, Inc. (“Amphastar”). All insulin inventory on hand was written off and the full purchase commitment contract to purchase future insulin was accrued as a recognized loss on purchase commitments as of the end of 2016. Cost of Revenues – Collaborations and Services — Cost of revenues for collaborations and services includes material, labor costs, manufacturing overhead, and excess capacity costs. These costs, in addition to the write-offs of inventory, are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. Cost of revenues for collaborations and services also includes the cost of product development. Research and Development ("R&D") — Clinical trial expenses result from obligations under contracts with vendors, consultants and clinical site agreements in addition to internal costs associated with conducting clinical trials. R&D costs are expensed as incurred. Clinical study and certain research costs are recognized over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Nonrefundable advance payments for services to be received in the future for use in R&D activities are recorded as prepaid assets and expensed in the period when the services are performed. Cash and Cash Equivalents — The Company considers all highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase, that are readily convertible into cash to be cash equivalents. As of June 30, 2023 and December 31, 2022 , cash equivalents were comprised of money market funds, corporate bonds and commercial paper with original maturities less than 90 days from the date of purchase. Held-to-Maturity Investments — The Company’s investments generally consist of commercial paper, corporate notes or bonds and U.S. Treasury securities. As of June 30, 2023 and December 31, 2022, the Company held short-term and long-term investments of debt securities, including commercial paper and bonds. The Company assesses whether it has any intention to sell the investment before maturity, whether any declines in fair value are the result of credit losses, as well as whether there were other-than-temporary impairments associated with the available for sale investment. The Company intends to hold its investments until maturity; therefore, these investments are stated at amortized cost. The investments with maturities less than 12 months are included in short-term investments and investments with maturities in excess of twelve months are included in long-term investments in the condensed consolidated balance sheets. The amortization or accretion of the Company’s investments is recognized as interest income in the condensed consolidated statements of operations. Available-for-Sale Investment — In June 2021, the Company purchased a $ 3.0 million convertible promissory note (the “Thirona convertible note”) issued by Thirona Bio, Inc. (“Thirona”). In January 2022, the Company purchased an additional $ 5.0 million convertible promissory note issued by Thirona. Unless earlier converted into conversion shares pursuant to the note purchase agreement, the principal and accrued interest shall be due and payable by Thirona on demand by the Company at any time after the maturity date. The Thirona convertible notes were amended in February 2023, which extended the maturity date from December 31, 2022 to June 30, 2024. The Thirona convertible notes are general unsecured obligations of Thirona and accrue interest at a rate of 6 % per annum. The Thirona convertible notes are classified as available-for-sale securities and are included in prepaid expenses and other current assets in the condensed co

Acquisition

Acquisition	6 Months Ended
	Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisition	2. Acquisition In May 2022 , the Company purchased certain assets and assumed certain liabilities associated with the V-Go wearable insulin delivery device from Zealand Pharma A/S and Zealand Pharma US, Inc. (together “Zealand”). Under the terms of the agreement with Zealand, the Company paid up-front consideration of $ 15.3 million for certain assets and assumed liabilities related to V-Go. In addition, the Company will be obligated to make one-time sales-based milestone payments to Zealand totaling up to a maximum of $ 10.0 million upon the achievement of specified annual revenue milestones between $ 40 million and $ 100 million. The total purchase consideration for V-Go was as follows (in thousands): Fair value of consideration: Amount Cash consideration $ 15,341 Fair value of contingent consideration (1) 610 Total $ 15,951 ____________________________ (1) Subsequent changes in the fair value are reported in general and administrative expenses. As of June 30, 2023, the fair value of the contingent milestone liability was $ 0.6 million. The fair value of the contingent milestone liability as of December 31, 2022 was consistent with the fair value on the acquisition date. The fair value of the contingent milestone liability was estimated using the Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.92 %, dividend yield of 0 %, volatility of 43 %, period of 15 years and credit risk of 17 %. The transaction was accounted for using the acquisition method of accounting, which requires, among other things, the assets acquired and liabilities assumed to be recognized at their respective fair values as of the acquisition date. The excess of the purchase price over those fair values was recorded as goodwill, which will be amortized over a period of 15 years for tax purposes. The estimates and assumptions used include the projected timing and amount of future cash flows and discount rates to reflect the risk inherent in the future cash flows. In May 2023, the Company finalized the fair value for assets acquired and liabilities assumed for V-Go. Inventory of $ 11.2 million consisted of raw materials, semi-finished goods and finished goods. The fair value of the inventory was determined based on the estimated selling price to be generated from the finished goods, less costs to sell, including a reasonable margin, which are level 3 inputs not observable in the market. Property and equipment and assumed liabilities were recorded at their carrying amounts which were deemed to approximate their fair values based on level 3 unobservable inputs. The fair values of the right-of-use assets and lease liabilities for assumed operating leases were assessed in accordance with ASC 842, Leases , based on discounted cash flow from lease payments, utilizing the Company’s incremental borrowing rate of 7.25 %. The fair value of the intangible asset was determined by applying the income approach based on significant level 3 unobservable inputs. The income approach estimates fair value based on the present value of cash flow that the assets could be expected to generate in the future. The Company developed internal estimates for expected cash flows in the present value calculation using inputs and significant assumptions that include historical revenues and earnings, long-term growth rate, discount rate, contributory asset charges and future tax rates, among others. The information below reflects the amounts of identifiable assets acquired and liabilities assumed as of May 31, 2023 (in thousands): Amount Assets: Inventory (1) $ 11,152 Property and equipment 2,921 Goodwill (1) 1,931 Intangible asset - Developed technology 1,200 Operating lease right-of-use assets 1,812 Total assets 19,016 Liabilities: Liabilities assumed (1) 1,253 Operating lease liability 1,812 Total liabilities 3,065 Net assets acquired $ 15,951 ___________________________ (1) Through May 2023, goodwill related to the acquisition of V-Go was adjusted for a reduction in rebate-related liabilities partially offset by a reserve for inventory obsolescence. There were no acquisition-related costs incurred during the three and six months ended June 30, 2023. Supplemental Pro Forma Information (unaudited) For the three and six months ended June 30, 2023, net revenue for V-Go was $ 4.8 million and $ 10.0 million, respectively, and loss from operations was $ 0.5 million and $ 1.5 million, respectively. For each of the three and six month periods ended June 30, 2022, net revenue and loss from operations for V-Go was $ 2.1 million and $ 0.3 million, respectively. The following unaudited pro forma summary presents consolidated information of the Company as if the acquisition had occurred on January 1, 2022 (in thousands): Three Months Six Months 2023 2022 2023 2022 Net revenue $ 48,611 $ 24,992 $ 89,237 $ 43,082 Net loss ( 5,265 ) ( 28,763 ) ( 15,060 ) ( 54,505 ) Net loss per share - basic and diluted ( 0.02 ) ( 0.11 ) ( 0.06 ) ( 0.22 ) These pro forma amounts have been calculated by applying the Company’s accounting policies assuming transaction costs had been incurred beginning January 1, 2022. The Company did not have any other material nonrecurring pro forma adjustments directly attributable to the acquisition included in the reported pro forma revenue and loss.

Investments

Investments	6 Months Ended
	Jun. 30, 2023
Schedule of Investments [Abstract]
Investments	3. Investments Cash Equivalents — Cash equivalents consist of highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase that are readily convertible into cash. Available-for-Sale Investment — The Thirona convertible notes are classified as available-for-sale securities and are included in prepaid expenses and other current assets in the condensed consolidated balance sheets. Available-for-sale investments are subsequently measured at fair value with realized gains and losses reported in other income (expense) in the condensed consolidated statements of operations. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income until realized. The Company determines fair value of its available-for-sale investments using level 3 inputs. The Company evaluates the fair value of its investment in Thirona by applying a Monte Carlo simulation model. For the three and six months ended June 30, 2023, the Company recognized $ 0.1 million and $ 0.2 million, respectively, of interest income on investment and $ 0.1 million and $ 0.2 million of interest income on investment, respectively, for the three and six months ended June 30, 2022. As of June 30, 2023 and December 31, 2022 , the fair value of the Company's investment in Thirona was $ 8.4 million and $ 7.1 million, respectively. For the three and six months ended June 30, 2023 , the Company recognized a gain of $ 0.9 million on its investment in Thirona as a result of the recovery of a temporary impairment, as well as an unrealized holding gain of $ 0.4 million. Held-to-Maturity Investments — Investments consist of highly liquid investments that are intended to facilitate liquidity and capital preservation. The amortization or accretion of the Company’s investments is recognized as interest income in the condensed consolidated statements of operations. For the three and six months ended June 30, 2023 , the Company recognized $ 1.0 million and $ 2.2 million, respectively, of interest income on investments and $ 0.4 million, for each respective period, of amortization on certain investments. For the three and six months ended June 30, 2022 , the Company recognized $ 0.5 million and $ 0.9 million, respectively, of interest income on investments, and $ 0.2 million and $ 0.5 million, respectively, of amortization on certain investments. No allowance for credit losses on held-to-maturity securities was required as of June 30, 2023. The contractual maturities of the Company’s held to maturity investments are summarized below (in thousands): June 30, 2023 December 31, 2022 Amortized Aggregate Amortized Aggregate Due in one year or less (1) $ 133,088 $ 132,864 $ 152,862 $ 156,976 Due after one year through five years 2,282 2,258 1,961 1,948 Total $ 135,370 $ 135,122 $ 154,823 $ 158,924 ___________________________ (1) The investments due in one year or less include cash equivalents of $ 74.9 million as of June 30, 2023 and $ 51.8 million as of December 31, 2022. The fair value of the cash equivalents, long-term and short-term investments are disclosed below (dollars in thousands). June 30, 2023 Investment Level Amortized Cost Gross Unrealized Estimated Commercial bonds and paper Level 2 $ 46,369 $ ( 108 ) $ 46,261 Money market funds Level 1 73,479 6 73,485 U.S. Treasuries Level 2 15,522 ( 146 ) 15,376 Total cash equivalents and investments 135,370 ( 248 ) 135,122 Less: cash equivalents 74,925 — 74,925 Total Investments $ 60,445 $ ( 248 ) $ 60,197 December 31, 2022 Investment Level Amortized Cost Gross Unrealized Estimated Commercial bonds and paper Level 2 $ 66,762 $ ( 594 ) $ 66,168 Money market funds Level 1 51,783 — 51,783 U.S. Treasuries Level 2 36,278 ( 587 ) 35,691 Total cash equivalents and investments 154,823 ( 1,181 ) 153,642 Less: cash equivalents 51,783 — 51,783 Total Investments $ 103,040 $ ( 1,181 ) $ 101,859 As of June 30, 2023 , there was $ 0.2 million of amounts receivable included in our condensed consolidated balance sheets as prepaid expenses and other current assets, which consisted of a de minimis amount of accrued interest receivable and $ 0.2 million of amount receivable on matured investment. As of December 31, 2022 , there was $ 0.6 million of accrued interest receivable and $ 5.1 million of amount receivable on matured investment.

Accounts Receivable

Accounts Receivable	6 Months Ended
	Jun. 30, 2023
Receivables [Abstract]
Accounts Receivable	4. Accounts Receivable Accounts receivable, net consists of the following (in thousands): June 30, 2023 December 31, 2022 Accounts receivable – commercial Accounts receivable, gross $ 20,078 $ 19,359 Wholesaler distribution fees and prompt pay discounts ( 3,319 ) ( 2,536 ) Reserve for returns ( 4,316 ) ( 4,108 ) Total accounts receivable – commercial, net 12,443 12,715 Accounts receivable – collaborations and services 15,346 4,086 Total accounts receivable, net $ 27,789 $ 16,801 As of June 30, 2023 and December 31, 2022, the allowance for doubtful accounts for commercial accounts receivable was de minimis . The Company had three wholesale distributors representing approximately 78 % of commercial accounts receivable as of June 30, 2023 and approximately 71 % of gross sales for each of the three and six months ended June 30, 2023. As of December 31, 2022 , the Company had three wholesale distributors representing approximately 79 % of commercial accounts receivables. As of June 30, 2023 and December 31, 2022 , there was no allowance for credit losses for accounts receivable for collaborations and services. The Company had one collaboration partner, UT, that comprised 100 % of the collaboration and services net accounts receivable as of June 30, 2023 and December 31, 2022 and approximately 100 % of gross revenue from collaborations and services for the three and six months ended June 30, 2023 .

Inventories

Inventories	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Inventories	5. Inventories Inventories consist of the following (in thousands): June 30, 2023 December 31, 2022 Raw materials $ 5,859 $ 5,739 Work-in-process 10,698 13,815 Finished goods 8,733 2,218 Total inventory $ 25,290 $ 21,772 Work-in-process and finished goods as of June 30, 2023 and December 31, 2022 include conversion costs and exclude the cost of insulin. All insulin inventory on hand was written off and the projected loss on the purchase commitment contract to purchase future insulin was accrued as of the end of 2016. Raw materials inventory included $ 0.8 million of pre-launch inventory as of June 30, 2023 and December 31, 2022, which consisted of FDKP received in November 2019. The Company expects to request approval from the FDA for the new source of FDKP in 2024. The Company analyzed its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company also performed an assessment of projected sales and evaluated the lower of cost or net realizable value and the potential excess inventory on hand as of June 30, 2023 and December 31, 2022 . Inventory that was forecasted to become obsolete due to expiration as well as inventory that does not meet acceptable standards is recorded in costs of goods sold in the condensed consolidated statements of operations. As a result of this assessment, there was an inventory write-off of $ 1.0 million and $ 3.4 million for the three and six months ended June 30, 2023 , respectively. For the three and six months ended June 30, 2022, there was an inventory write-off of $ 0.5 million as a result of this assessment.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	6. Property and Equipment Property and equipment consists of the following (dollars in thousands): Estimated Useful Life (Years) June 30, 2023 December 31, 2022 Land — $ 875 $ 875 Buildings 39 - 40 17,389 17,389 Building improvements 5 - 40 43,527 38,952 Machinery and equipment 3 - 15 58,905 58,542 Furniture, fixtures and office equipment 5 - 10 2,976 2,976 Computer equipment and software 3 8,646 8,246 Construction in progress — 37,412 16,706 Total property and equipment 169,730 143,686 Less accumulated depreciation ( 100,220 ) ( 98,560 ) Total property and equipment, net $ 69,510 $ 45,126 Depreciation expense related to property and equipment was as follows (in thousands): Three Months Six Months 2023 2022 2023 2022 Depreciation Expense $ 1,095 $ 727 $ 2,133 $ 1,326 In November 2021 , the Company sold certain land, building and improvements located in Danbury, CT (the “Property”) to an affiliate of Creative Manufacturing Properties (the “Purchaser”) for a sales price of $ 102.3 million, subject to terms and conditions contained in a purchase and sale agreement. Effective with the closing of this transaction, the Company entered into a 20 -year lease agreement with the Purchaser (the “Sale-Leaseback Transaction”). The sale of the Property and subsequent lease did not result in the transfer of control of the Property to the Purchaser; therefore, the Sale-Leaseback Transaction qualified as a failed sale leaseback transaction whereby the lease is accounted for as a finance lease and the Property remains as a long-lived asset of the Company and is depreciated at its remaining useful life of 20 years or less. See Note 15 – Commitments and Contingencies .

Goodwill and Other Intangible A

Goodwill and Other Intangible Asset	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Asset	7. Goodwill and Other Intangible Asset Goodwill — Goodwill represents the excess of the purchase price over the identifiable tangible and intangible assets acquired plus liabilities assumed arising from business combinations. The balance of goodwill was approximately $ 1.9 million and $ 2.4 million as of June 30, 2023 and December 31, 2022, respectively, as a result of the Company's acquisition of V-Go in May 2022. Through May 2023, goodwill related to the acquisition of V-Go was adjusted for a reduction in rebate-related liabilities partially offset by a reserve for inventory obsolescence. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. See Note 1 – Description of Business and Significant Accounting Policies . Other Intangible Asset — Other intangible asset consisted of the following (dollars in thousands): Estimated June 30, 2023 December 31, 2022 Useful Cost Accumulated Net Book Value Cost Accumulated Net Book Value Developed technology 15 $ 1,200 $ ( 87 ) $ 1,113 $ 1,200 $ ( 47 ) $ 1,153 Amortization expense related to the other intangible asset was de minimis for the six months ended June 30, 2023. The estimated annual amortization expense for the other intangible asset for the years ended December 31, 2023 through 2027 will be approximately $ 0.1 million per year and $ 0.6 million, thereafter. The Company evaluates its other intangible asset for potential impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. See Note 1 – Description of Business and Significant Accounting Policies .

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	8. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities were comprised of the following (in thousands): June 30, 2023 December 31, 2022 Salary and related expenses $ 12,140 $ 14,906 Discounts and allowances for commercial product sales 10,153 8,504 Accrued interest (1) 6,267 2,201 Current portion of milestone rights liability (2) 1,676 924 Deferred lease liability 944 1,304 Professional fees 818 1,136 Returns reserve for acquired product 633 1,013 Danbury facility buildout 93 846 Other 4,109 4,719 Accrued expenses and other current liabilities $ 36,833 $ 35,553 _________________________ (1) As of June 30, 2023, accrued interest includes $ 4.1 million related to a milestone payment of $ 5.0 million to be paid in the third quarter of 2023. (2) As of June 30, 2023, the current portion of milestone rights liability includes $ 0.9 million to be paid in the third quarter of 2023 and $ 0.8 million reclassed from long-term to short-term milestone right liability.

Borrowings

Borrowings	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Borrowings	9 . Borrowings Carrying amount of the Company's borrowings consist of the following (in thousands): June 30, 2023 December 31, 2022 Senior convertible notes $ 226,124 $ 225,397 MidCap credit facility 39,478 39,264 Mann Group convertible note 8,829 8,829 Total debt – net carrying amount $ 274,431 $ 273,490 The following table provides a summary of the Company’s principal balance of debt and key terms: Amount Due Terms June 30, 2023 December 31, 2022 Annual Interest Maturity Date Conversion Price Senior convertible notes $ 230.0 million $ 230.0 million 2.50 % March 2026 $ 5.21 MidCap credit facility (1) $ 40.0 million $ 40.0 million one-month 1 % floor) 6.25 %; 8.25 % (1 ) August 2025 (1 ) N/A Mann Group convertible note $ 8.8 million $ 8.8 million 2.50 % December 2025 $ 2.50 _________________________ (1) In August 2022, the Company amended the MidCap credit facility and transitioned the benchmark interest rate from LIBOR to the Secured Overnight Financing Rate (“SOFR”). The maturities of the Company’s borrowings as of June 30, 2023 are as follows (in thousands): Amounts 2023 $ 6,667 2024 20,000 2025 22,163 2026 230,000 Total principal payments 278,830 Unamortized discount ( 521 ) Debt issuance costs ( 3,878 ) Total debt $ 274,431 Senior convertible notes – In March 2021, the Company issued $ 230.0 million aggregate principal amount of Senior convertible notes in a private offering. The Senior convertible notes were issued pursuant to an indenture, dated March 4, 2021 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Senior convertible notes are general unsecured obligations of the Company and will mature on March 1, 2026 , unless earlier converted, redeemed or repurchased. The Senior convertible notes will bear cash interest from March 4, 2021 at an annual rate of 2.50 % payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2021. The Senior convertible notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding December 1, 2025, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock, par value $ 0.01 per share, for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130 % of the conversion price for the Senior convertible notes on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period in which the trading price (as defined in the Indenture) per $ 1,000 principal amount of the Senior convertible notes for each trading day of the measurement period was less than 98 % of the product of the last reported sale price of the common stock and the conversion rate on each such trading day; (3) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Senior convertible notes called (or deemed called) for redemption; or (4) upon the occurrence of specified corporate events as set forth in the Indenture. On or after December 1, 2025 until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. The initial conversion rate is 191.8281 shares of common stock per $ 1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $ 5.21 per share of common stock). The initial conversion price of the Senior convertible notes represents a premium of approximately 30 % to the last reported sale price of the common stock on the Nasdaq Global Market on March 1, 2021. The conversion rate for the Senior convertible notes is subject to adjustment under certain circumstances in accordance with the terms of the Indenture, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date of the Senior convertible notes or if the Company delivers a notice of redemption in respect of the Senior convertible notes, the Company will, in certain circumstances, increase the conversion rate of the Senior convertible notes for a holder who elects to convert its Senior convertible notes in connection with such a corporate event or convert its Notes called for redemption during the related redemption period (as defined in the Indenture), as the case may be. The Company may not redeem the Senior convertible notes prior to March 6, 2024 . The Company may redeem for cash all or any portion of the Senior convertible notes, at its option, on or after March 6, 2024 and prior to the 36th scheduled trading day immediately preceding the maturity date, if the last reported sale price of common stock has been at least 130 % of the conversion price for the Senior convertible notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100 % of the principal amount of the Senior convertible notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company elects to redeem less than all of the outstanding Senior convertible notes, at least $ 75.0 million aggregate principal amount of Senior convertible notes must be outstanding and not subject to redemption as of the relevant redemption notice date. No sinking fund is provided for the Senior convertible notes. If the Company undergoes a fundamental change (as defined in the Indenture), then, subject to certain conditions and except as described in the Indenture, holders may require the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100 % of the principal amount of the Senior convertible notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture includes customary covenants and sets forth certain events of default after which the Senior convertible notes may be declared immediately due and payable. If certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries) occur, 100 % of the principal of and accrued and unpaid interest on the Senior convertible notes will automatically become due and payable. If an event of default with respect to the Senior convertible notes, other than certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries), occurs and is continuing, the trustee, by notice to the Company, or the holders of at least 25% in principal amount of the outstanding Senior convertible notes by notice to the Company and the trustee, may, and the trustee at the request of such holders shall, declare 100 % of the principal of and accrued and unpaid interest, if any, on all the Senior convertible notes to be due and payable. Notwithstanding the foregoing, the Indenture provides that, to the extent the Company so elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 365 days after the occurrence of such an event of default consist exclusively of the right to receive additional interest on the Senior convertible notes as set forth in the Indenture . The Indenture provides that the Company shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of the consolidated properties and assets of the Company and its subsidiaries, taken as a whole, to, another person (other than any such sale, conveyance, transfer or lease to one or more of the Company’s direct or indirect wholly owned subsidiaries), unless: (i) the resulting, surviving or transferee person (if not the Company) is a corporation organized and existing under the laws of the United States of America, any State thereof or the District of Columbia, and such corporation (if not the Company) expressly assumes by supplemental indenture all of the Company’s obligations under the Senior convertible notes and the Indenture; and (ii) immediately after giving effect to such transaction, no default or event of default has occurred and is continuing under the Indenture. The Company’s net proceeds from the March 2021 offering were approximately $ 222.7 million, after deducting the initial purchasers’ discounts and commissions and the estimated offering expenses payable by the Company. As of June 30, 2023 , the unamortized debt issuance cost was $ 3.9 million. MidCap credit facility — In August 2019, the Company entered into the MidCap credit facility and borrowed the first advance of $ 40.0 million (“Tranche 1”) in August 2019 and the second advance of $ 10.0 million (“Tranche 2”) in December 2020. In April 2021, $ 10.0 million was prepaid. Under the terms of the MidCap credit facility, a third advance of $ 60.0 million (“Tranche 3”) became available to the Company after the Tyvaso DPI approval by the FDA through June 30, 2022 (see Note 10 – Collaboration, Licensing and Other Arrangements ). The Company did not exercise its right to borrow Tranche 3. The MidCap credit facility has been amended several times, including in April 2021 when the parties agreed to, among other things, (i) increase the amount available under the third advance from $ 25.0 million to $ 60.0 million and extend the date through which the third advance is available to June 30, 2022 , (ii) amend the conditions to the third advance of $60.0 million being available to draw, including certain milestone conditions associated with Tyvaso DPI, (iii) remove the Company’s obligation to issue a warrant to purchase shares of the Company’s common stock upon drawing down the third advance, (iv) extend the interest-only period until September 1, 2023 and extend the maturity date until August 1, 2025 , (v) amend the financial covenant relating to trailing 12 month minimum Afrezza net revenue, (vi) decrease the minimum cash covenant, (vii) decrease the interest rate on any amounts outstanding, now or in the future, under the MidCap credit facility, (viii) permit the Company to make certain acquisitions, subject to requirements, and (ix) permit the Company to make investments of up to an additional $ 9.0 million so long as the Company has $ 90.0 million or more of unrestricted cash and short-term investments following such investment. Concurrent with entering into this amendment, the Company made a $ 10.0 million principal prepayment against outstanding term loans under the MidCap credit facility and paid a related $ 1.0 million exit fee in lieu of the unaccrued portion of the original exit fee and prepayment penalties that would otherwise have been due with respect to the partial prepayment. The prepayment penalty of $ 1.0 million related to the payment of $ 10.0 million was capitalized and will be amortized over the remaining life of the debt. As of June 30, 2023 , the unamortized debt discount was $ 0.2 million and the unamortized prepayment penalty was $ 0.4 million. In August 2022, the Company entered into the tenth amendment to the MidCap credit facility to change the benchmark interest rate from LIBOR to the Secured Overnight Financing Rate (“SOFR”). Tranche 1 and Tranche 2 accrue interest at an annual rate equal to the lesser of (i) 8.25 % and (ii) the one-month SOFR (subject to a one-month SOFR floor of 1.00 %) plus 6.25 %. Interest on each term loan advance is due and payable monthly in arrears. Principal on each term loan advance under Tranche 1 and Tranche 2 are payable in 24 equal monthly installments beginning September 1, 2023 , until paid in full on August 1, 2025 . The Company has the option to prepay its existing term loans, in whole or in part, subject to early termination fees in an amount equal to 1.00 % of principal prepaid. The Company’s obligations under the MidCap credit facility are secured by a security interest on substantially all of its assets, including intellectual property. The MidCap credit facility, as amended, contains customary affirmative covenants and customary negative covenants limiting the Company’s ability and the ability of the Company’s subsidiaries to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions. The Company must also comply with a financial covenant relating to trailing twelve month minimum Afrezza net revenue, tested on a monthly basis, unless the Company has $ 90.0 million or more of unrestricted cash and short-term investments. As of June 30, 2023, the Company was in compliance with the financial covenant. The MidCap credit facility also contains customary events of default relating to, among other things, payment defaults, breaches of covenants, a material adverse change, listing of the Company’s common stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments, and inaccuracies of representations and warranties. Upon an event of default, the agent and the lenders may declare all or a portion of the Company’s outstanding obligations to be immediately due and payable and exercise other rights and remedies provided for under the MidCap credit facility. During the existence of an event of default, interest on the term loans could be increased by 2.00 %. Mann Group convertible note — In August 2019, the Company issued a $ 35.0 million note that is convertible into shares of the Company’s common stock at $ 2.50 per share (the “Mann Group convertible note”) as part of a restructuring of its then existing indebtedness to Mann Group. The Mann Group convertible note originally accrued interest at the rate of 7.00 % per year on the principal amount, payable quarterly in arrears on the first day of each calendar quarter beginning October 1, 2019 . In April 2021, the Company and Mann Group amended the Mann Group convertible note, pursuant to which the parties agreed to (i) reduce the interest rate from 7.0% to 2.5 % effective on April 22, 2021, and (ii) extend the maturity date from November 3, 2024 to December 31, 2025 . The principal and any accrued and unpaid interest under the Mann Group convertible note may be converted, at the option of Mann Group, at any time on or prior to the close of business on the business day immediately preceding the stated maturity date, into shares of the Company’s common stock at a conversion rate of 400 shares per $ 1,000 of principal and/or accrued and unpaid interest, which is equal to a conversion price of $ 2.50 per share. The conversion rate will be subject to adjustment under certain circumstances described in the Mann Group convertible note. Interest on the convertible note will be payable in kind by adding the amount thereof to the principal amount; provided that with respect to interest accruing from and after January 1, 2021, the Company may, at its option, elect to pay any such interest on any interest payment date, if certain conditions are met, in shares of the Company’s common stock at a price per shall equal to the last reported sale price on the trading day immediately prior to the payment date. During the six months ended June 30, 2023, the Company paid interest on the Mann Group convertible note by issuing 23,683 shares of common stock. During the six months ended June 30, 2022, Mann Group converted $ 10.0 million of principal and capitalized interest into 4,000,000 shares of common stock. In addition, the Company paid quarterly interest by issuing the Mann Group 31,541 shares of common stock. Amortization of the premium and accretion of debt issuance costs related to all borrowings were as follows (in thousands): Three Months Six Months 2023 2022 2023 2022 Amortization of debt discount $ 108 $ 106 $ 214 $ 212 Amortization of debt issuance cost 363 363 727 726 Milestone Rights — As of June 30, 2023 and December 31, 2022, the remaining Milestone Rights liability balance was $ 4.8 million, which was based on initial fair value estimates calculated using the income approach and reduced by milestone achievement payments made. As of June 30, 2023 and December 31, 2022, the Milestone Rights liability consisted of $ 1.7 million of current liability which was presented as accrued expenses and other current liabilities, and $ 3.2 million of long-term liability which was presented as milestone liabilities in our condensed consolidated balance sheets. The Milestone Rights Agreement includes customary representations and warranties and covenants by the Company, including restrictions on transfers of intellectual property related to Afrezza. The Milestone Rights are subject to acceleration in the event the Company transfers its intellectual property related to Afrezza in violation of the terms of such agreement.

Collaboration, Licensing and Ot

Collaboration, Licensing and Other Arrangements	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration, Licensing and Other Arrangements	10. Collaboration, Licensing and Other Arrangements Revenue from collaborations and services were as follows (in thousands): Three Months Six Months 2023 2022 2023 2022 UT CSA Agreement (1) $ 10,933 $ 4,695 $ 22,097 $ 5,879 UT License Agreement (2) 242 698 427 1,556 Cipla License and Distribution Agreement 36 36 73 73 Vertice Pharma Co-Promotion Agreement — 325 — 325 Other — 114 — 201 Total revenue from collaborations and services $ 11,211 $ 5,868 $ 22,597 $ 8,034 _________________________ (1) Amount consists of revenue recognized for Manufacturing Services and sales of product to UT for the periods presented. (2) Amounts consist of revenue recognized for Next-Gen R&D Services and R&D Services and License for the periods presented. United Therapeutics License Agreement — In September 2018, the Company and UT entered into an exclusive global license and collaboration agreement (the “UT License Agreement”), pursuant to which UT is responsible for global development, regulatory and commercial activities with respect to Tyvaso DPI. The Company is responsible for manufacturing Tyvaso DPI. Total revenue from UT was as follows (in thousands): Three Months Six Months 2023 2022 2023 2022 UT Revenue UT CSA Agreement $ 10,933 $ 4,695 $ 22,097 $ 5,879 UT License Agreement 242 698 427 1,556 Royalties — Collaborations (1) 19,055 304 30,733 304 Total revenue from UT $ 30,230 $ 5,697 $ 53,257 $ 7,739 _________________________ (1) Amount consists of royalties associated with the UT License Agreement. The contract assets related to the royalties is included in prepaid expense and other current assets in the condensed consolidated balance sheets. In October 2018, the Company and UT entered into the UT License Agreement for the collaboration and development of Tyvaso DPI. Pursuant to this agreement, the Company also receives low double-digit royalties on net sales of Tyvaso DPI as well as a manufacturing margin on commercial supplies of the product. In August 2021, the Company and UT entered into the CSA, pursuant to which the Company is responsible for manufacturing and supplying to UT, and UT is responsible for purchasing from the Company on a cost-plus basis. There have been various amendments to the UT License Agreement and the CSA since inception. The terms of the amendments and related accounting treatment are disclosed in the Company's Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on February 23, 2023. In December 2022, the Company and UT agreed to fund an additional $ 39.5 million to support capital and continuous improvement activities and $ 2.3 million in the development of alternative manufacturing processes. The Company determined that the capital and continuous improvements should be combined with the manufacturing services performance obligation and the alternative manufacturing processes should be combined with the Next-Gen R&D Services. The total revised anticipated cash flows of $ 722.3 million from the transaction was allocated to the three distinct performance obligations as follows (dollars in millions): Anticipated Cash Flow Revenue Allocation Recognition Method Progress Measure Revenue Total anticipated cash flow (1) $ 722.3 Distinct Performance Obligation R&D Services and License $ — Over time Ratably Aug 2021 - Oct 2021 Next-Gen R&D Services $ 10.0 Over time Input % of completion of costs Manufacturing Services and (2) $ 712.3 Point in time Transfer of control __________________________ (1) The total anticipated cash flow includes a transaction price of $ 120.0 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $ 602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA. (2) The Manufacturing Services performance obligation will be recognized as control of manufactured products is transferred to UT. The modification did not result in a cumulative catch-up adjustment as a result of the revenue being deferred for the performance obligations that were affected by the modification. The allocation of the transaction price for the Manufacturing Services includes a material right related to the Company’s estimated production of product in the amount of $ 220.8 million. The Company will sell product to UT under individual purchase orders, which represent distinct performance obligations. The ultimate cash flows may vary as manufacturing purchase orders are received. As of June 30, 2023 , deferred revenue consisted of $ 62.3 million, of which $ 3.3 million was classified as current and $ 59.0 million was classified as long-term on the condensed consolidated balance sheet. As of December 31, 2022 , deferred revenue consisted of $ 37.9 million, of which $ 1.6 million was classified as current and $ 36.3 million was classified as long-term on the condensed consolidated balance sheet. Thirona Collaboration Agreement — In June 2021, the Company and Thirona entered into a collaboration agreement to evaluate the therapeutic potential of Thirona’s compound for the treatment of pulmonary fibrosis. If initial studies are promising, the Company can exercise certain rights to seek a full license to the compound for clinical development and commercialization. The parties will perform their respective obligations and provide reasonable support for research, clinical development and regulatory strategy. The collaboration agreement was accounted for under ASC 808, Collaborative Agreements; however, no consideration was exchanged between the parties. The costs incurred by the Company were expensed as R&D in the condensed consolidated statements of operations. On February 28, 2023, the collaboration agreement was amended to extend the term through June 2024. In accordance with the amendment, the Company will fund a minimum of $ 1.1 million to be expended on a revised development plan prepared by Thirona. Biomm Supply and Distribution Agreement — In May 2017, the Company and Biomm S.A. ("Biomm") entered into a supply and distribution agreement for the commercialization of Afrezza in Brazil. Under this agreement, Biomm was responsible for pursuing regulatory approvals of Afrezza in Brazil, including from the Agência Nacional de Vigilância Sanitária (“ANVISA”) and, with respect to pricing matters, from the Camara de Regulação de Mercado de Medicamentos (“CMED”), both of which were received. Biomm commenced product sales in January 2020. There were no shipments of product to Biomm in 2022 or the first six months of 2023. Cipla License and Distribution Agreement — In May 2018 , the Company and Cipla Ltd. (“Cipla”) entered into an exclusive agreement for the marketing and distribution of Afrezza in India and the Company received a $ 2.2 million nonrefundable license fee. Under the terms of the agreement, Cipla is responsible for obtaining regulatory approvals to distribute Afrezza in India and for all marketing and sales activities of Afrezza in India. The Company is responsible for supplying Afrezza to Cipla. The Company has the potential to receive an additional regulatory milestone payment, minimum purchase commitment revenue and royalties on Afrezza sales in India once cumulative gross sales have reached a specified threshold. The nonrefundable licensing fee was recorded in deferred revenue and is being recognized in net revenue – collaborations over 15 years, representing the estimated period to satisfy the performance obligation. The additional milestone payments represent variable consideration for which the Company has not recognized any revenue because of the uncertainty of obtaining marketing approval. As of June 30, 2023 , the deferred revenue balance was $ 1.4 million, of which $ 0.1 million is classified as current and $ 1.3 million is classified as long term in the condensed consolidated balance sheets.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	11. Fair Value of Financial Instruments The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. The Company uses the exit price method for estimating the fair value of loans for disclosure purposes. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy, as follows: Level 1 — Quoted prices for identical instruments in active markets. Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 — Significant inputs to the valuation model are unobservable. The carrying amounts reported in the condensed consolidated financial statements for cash, accounts receivable, accounts payable, and accrued expenses and other current liabilities (excluding the Milestone Rights liability) approximate their fair value due to their relatively short maturities. The fair value of the Senior convertible notes, MidCap credit facility, Mann Group convertible note, Milestone Rights liability and Financing liability are disclosed below. Financial Liabilities — The following tables set forth the fair value of the Company’s financial instruments (in thousands): June 30, 2023 Fair Value Carrying Amount Significant Financial liabilities: Senior convertible notes (1) $ 226,124 $ 241,904 MidCap credit facility (2) 39,478 41,721 Mann Group convertible note (3) 8,829 16,316 Milestone rights (4) 4,838 11,800 Contingent milestone liability (4) 610 610 Financing liability (5) 104,081 103,229 _________________________ (1) Fair value was determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 11 %, volatility of 72.9 % and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or – 2 % would result in a fair value of $ 233.4 million and $ 250.9 million, respectively. (2) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 12 %. A change in yield of + or – 2 % would result in a fair value of $ 40.9 million and $ 42.6 million, respectively. (3) The fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 13 % and volatility of 72.3 % to the straight note and a binomial option pricing model for the value of the conversion feature. A change in yield of + or – 2 % would result in a fair value of $ 16.0 million and $ 16.6 million, respectively. (4) Fair value was determined by applying a Monte Carlo simulation. (5) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 10 %. December 31, 2022 Fair Value Carrying Value Significant Financial liabilities: Senior convertible notes (1) $ 225,397 $ 253,864 MidCap credit facility (2) 39,264 41,070 Mann Group convertible note (3) 8,829 20,836 Milestone rights (4) 4,838 12,600 Contingent milestone liability (4) 610 960 Financing liability (5) 104,077 103,239 _________________________ (1) Fair value was determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 13 %, volatility of 75.8 % and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or – 2 % would result in a fair value of $ 245.0 million and $ 263.4 million, respectively. (2) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 12 %. A change in yield of + or – 2 % would result in a fair value of $ 40.0 million and $ 42.4 million, respectively. (3) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 13 % and volatility of 77.8 % to the straight note and a binomial option pricing model for the value of the conversion feature. A change in yield of + or – 2 % would result in a fair value of $ 20.5 million and $ 21.2 million, respectively. (4) Fair value was determined by applying a Monte Carlo simulation. (5) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 10 %. Milestone Rights Liability — The fair value measurement of the Milestone Rights liability is sensitive to the discount rate and the timing of achievement of milestones. The Company utilized Monte-Carlo Simulation Method to simulate the Afrezza net sales under a neutral framework to estimate the payment. The Company then discounted the future expected payments at cost of debt with a term equal to the simulated time to payout based on cumulative sales. See Note 9 – Borrowings . Contingent milestone liability — The acquisition of V-Go in May 2022 resulted in a contingent milestone liability which could result in obligations to the seller if certain revenue thresholds are met. The initial fair value of the contingent milestone liability was recorded as an adjustment to the purchase price. Subsequent changes in the fair value are reported in general and administrative expenses. See Note 2 – Acquisition. Financing Liability — The Sale-Leaseback Transaction in November 2021 resulted in a financing liability. See Note 15 – Commitments and Contingencies .

Common and Preferred Stock

Common and Preferred Stock	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Common and Preferred Stock	12. Common and Preferred Stock In May 2023, the Company’s stockholders, upon recommendation of the Company’s board of directors approved an amendment to our Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 400,000,000 shares to 800,000,000 shares. The Company is authorized to issue 800,000,000 shares of common stock, par value $ 0.01 per share, and 10,000,000 shares of undesignated preferred stock, par value $ 0.01 per share, issuable in one or more series as designated by the Company’s board of directors. No other class of capital stock is authorized. As of June 30, 2023 and December 31, 2022, 268,235,145 and 263,793,305 shares of common stock, respectively, were issued and outstanding and no shares of preferred stock were outstanding. In February 2018, the Company entered into a controlled equity offering sales agreement (the “CF Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor Fitzgerald, shares of the Company’s common stock having an aggregate offering price of up to $ 50.0 million or such other amount as may be permitted by the Sales Agreement. Under the Sales Agreement, Cantor Fitzgerald may sell shares by any method deemed to be an “at-the-market offering” as defined in Rule 415 under the Securities Act of 1933, as amended. For the six months ended June 30, 2023 , the Company sold 631,383 shares of common stock at a weighted average purchase price of $ 4.40 per share for gross proceeds of approximately $ 2.8 million pursuant to the CF Sales Agreement. There were no sales under the CF Sales Agreement for the six months ended June 30, 2022. During the six months ended June 30, 2023, the Company paid interest on the Mann Group convertible note by issuing 23,683 shares of common stock. During the six months ended June 30, 2022, Mann Group converted $ 10.0 million of principal and capitalized interest into 4,000,000 shares of common stock. In addition, the Company paid quarterly interest by issuing the Mann Group 31,541 shares of common stock. For the six months ended June 30, 2023, the Company received $ 0.2 million from the market price stock purchase plan (“MPSPP”) for 36,004 shares. For the six months ended June 30, 2022, the Company received $ 0.7 million from the MPSPP for 252,176 shares. For shares of common stock issued pursuant to the Company's 2004 employee stock purchase plan ("ESPP"), see Note 14 – Stock-Based Compensation Expense.

Earnings Per Common Share ("EPS

Earnings Per Common Share ("EPS")	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Earnings Per Common Share ("EPS")	13. Earnings per Common Share (“EPS”) Basic EPS excludes dilution for potentially dilutive securities and is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted EPS reflects the potential dilution under the treasury method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted EPS as they would be antidilutive. The following tables summarize the components of the basic and diluted EPS computations (in thousands, except per share amounts): Three Months Six Months 2023 2022 2023 2022 EPS — basic and diluted: Net loss (numerator) $ ( 5,265 ) $ ( 29,023 ) $ ( 15,060 ) $ ( 55,021 ) Weighted average common shares (denominator) 265,626 253,644 264,802 252,775 Net loss per share $ ( 0.02 ) $ ( 0.11 ) $ ( 0.06 ) $ ( 0.22 ) Common shares issuable represents incremental shares of common stock which consist of RSUs, options, warrants, and shares that could be issued upon conversion of the Senior convertible notes and the Mann Group convertible notes. Potentially dilutive securities outstanding that are considered antidilutive are summarized as follows (in shares): Six Months 2023 2022 Senior convertible notes 44,120,463 44,120,463 RSUs and Market RSUs (1) 16,951,734 15,848,183 Common stock options and PNQs 8,688,625 9,766,028 Mann Group convertible notes 3,370,000 3,370,000 Employee stock purchase plan — 235,794 Total shares 73,130,822 73,340,468 __________________________ (1) Market RSUs issued in 2021, 2022, and 2023 are included at the share delivery of 0 %, 162 %, and 100 %, respectively, in accordance with a valuation assessment obtained as of June 30, 2023 .

Stock-Based Compensation Expens

Stock-Based Compensation Expense	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation Expense	14. Stock-Based Compensation Expense In May 2023, the Company’s stockholders, upon recommendation of the Company’s board of directors, approved an amendment to the Company’s 2018 Equity Incentive Plan (the "2018 Plan") to increase the number of shares of common stock that may be issued under the 2018 Plan by 25,000,000 shares. During the six months ended June 30, 2023, the Company granted the following awards (in shares): Three Months Three Months Six Months 2023 2023 2023 Employee awards: RSUs 179,905 (1) 2,660,721 (2) 2,840,626 Market RSUs — 1,445,000 (3) 1,445,000 Non-employee director RSUs — 319,904 (4) 319,904 Total awards issued 179,905 4,425,625 4,605,530 _________________________ (1) RSUs had a weighted average grant date fair value of $ 4.16 per share, of which 91,900 RSUs had a cliff vesting period of three years , 42,000 RSUs had a cliff vesting period of two years , and 46,005 RSUs had a vesting period of 25 % annually over four years . (2) RSUs had a weighted average grant date fair value of $ 4.56 per share, of which 2,598,971 RSUs had a vesting period of 25 % annually over four years , and 61,750 RSUs had a cliff vesting period of 3 years . (3) Market RSUs had a grant date fair value of $ 9.40 per share and will vest on July 15, 2026 provided the closing price of the Company’s common stock on June 30, 2026 is not less than the closing price on July 1, 2023. The number of shares delivered on the vesting date is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until July 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile= 0 % of target, 25th percentile= 50 % of target, 50th percentile= 100 % of target, 75th percentile= 200 % of target, 90th percentile or higher= 300 % maximum. Payout values will be interpolated between the percentile rankings above. (4) RSUs had a weighted average grant date fair value of $ 4.55 per share and vested immediately upon the grant date; however, the underlying shares of common stock will not be delivered until there is a separation of service such as resignation, retirement or death. As of June 30, 2023 , unrecognized stock-based compensation expense was $ 0.2 million related to options and PNQs which is expected to be recognized over a weighted average period of 2.93 years as well as $ 24.0 million and $ 20.9 million related to RSUs and Market RSUs, respectively, which is expected to be recognized over weighted average periods of approximately 2.73 and 2.07 years, respectively. Total stock-based compensation expense recognized in the condensed consolidated statements of operations as cost of goods sold, cost of revenue – collaborations and services, R&D, selling and general and administrative expense was as follows (in thousands): Three Months Six Months 2023 2022 2023 2022 RSUs and options $ 5,404 $ 4,239 $ 8,882 $ 6,883 Employee stock purchase plan 176 183 353 345 Total $ 5,580 $ 4,422 $ 9,235 $ 7,228 Employee Stock Purchase Plan The Company provides all employees, including executive officers, the ability to purchase common stock at a discount under the Company’s 2004 the ESPP. The ESPP is designed to comply with Section 423 of the Internal Revenue Code and provides all employees with the opportunity to purchase up to $ 25,000 worth of common stock (based on the undiscounted fair market value at the commencement of the offering period) each year at a purchase price that is the lower of 85 % of the fair market value of the common stock on either the date of purchase or the commencement of the offering period. An employee may not purchase more than 5,000 shares of common stock on any purchase date. The executives’ rights under the ESPP are the same as those of all other employees. In May 2023, the Company’s stockholders, upon recommendation of the Company’s board of directors, approved an amendment to the Company’s ESPP to increase the number of shares of common stock authorized for issuance under the ESPP by an additional 3,000,000 shares. There were approximately 3.1 million shares of common stock available for issuance under the ESPP as of June 30, 2023 .

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies Guarantees and Indemnifications — In the ordinary course of its business, the Company makes certain indemnities, commitments and guarantees under which it may be required to make payments in relation to certain transactions. The Company, as permitted under Delaware law and in accordance with its Bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal and therefore has not recorded any liability for these indemnities in the condensed consolidated balance sheets. The Company accrues for losses for any known contingent liability, including those that may arise from indemnification provisions, when future payment is probable and the amount can be reasonably estimated. No such losses have been recorded to date. Litigation — The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. As of June 30, 2023, the Company believes that the final disposition of such matters will not have a material adverse effect on the results of operations, financial position, or cash flows of the Company and no accrual has been recorded. The Company maintains liability insurance coverage to protect the Company’s assets from losses arising out of or involving activities associated with ongoing and normal business operations. The Company records a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company’s policy is to accrue for legal expenses in connection with legal proceedings and claims as they are incurred. Contingencies — In July 2013, the Company entered into the Milestone Rights Agreement with the Original Milestone Purchasers, pursuant to which the Company granted the Milestone Rights to receive payments up to $ 90.0 million upon the occurrence of specified strategic and sales milestones, $ 60.0 million of which remains payable to the Milestone Purchasers upon achievement of such milestones (see Note 9 – Borrowings ). Sale-Leaseback Transaction — In November 2021, the Company sold the Property to the Purchaser for a sales price of $ 102.3 million, subject to terms and the conditions contained in a purchase and sale agreement. Effective with the closing of the Sale-Leaseback Transaction, the Company and the Purchaser entered into a lease agreement (the “Lease”), pursuant to which the Company leased the Property from the Purchaser for an initial term of 20 years, with four renewal options of five years each. The total annual rent under the Lease starts at approximately $ 9.5 million per year, subject to a 50% rent abatement during the first year of the Lease, and will increase annually by (i) 2.5% in the second through fifth year of the Lease and (ii) 3% in the sixth and each subsequent year of the Lease, including any renewal term. The Company is responsible for payment of operating expenses, property taxes and insurance for the Property. The Purchaser will hold a security deposit of $ 2.0 million during the Lease term. Pursuant to the terms of the Lease, the Company has four options to repurchase the Property, in 2026, 2031, 2036 and 2041, for the greater of (i) $ 102.3 million and (ii) the fair market value of the Property. Effective with the closing of the Sale-Leaseback Transaction, the Company and the Purchaser also entered into a right of first refusal agreement (the “ROFR”), pursuant to which the Company has a right to re-purchase the Property from the Purchaser in accordance with terms and conditions set forth in the ROFR. Specifically, if the Purchaser receives, and is willing to accept, a bona fide purchase offer for the Property from a third-party purchaser, the Company has certain rights of first refusal to purchase the Property on the same material terms as proposed in such bona fide purchase offer. As of June 30, 2023, the related financing liability was $ 104.1 million, which was recognized in the condensed consolidated balance sheet and of which $ 94.4 million was long-term and $ 9.7 million was current. As of December 31, 2022 , the related financing liability was $ 104.1 million, of which $ 94.5 million was long-term and $ 9.6 million was current. Financing liability information was as follows: June 30, 2023 December 31, 2022 Weighted average remaining lease term (in years) 18.3 18.8 Weighted average discount rate 9.0 % 9.0 % Three Months Six Months 2023 2022 2023 2022 Interest expense on financing liability $ 2,449 $ 2,443 $ 4,873 $ 4,814 The Company's remaining financing liability payments were as follows (in thousands): June 30, 2023 2023 $ 4,906 2024 10,018 2025 10,269 2026 10,533 2027 10,849 Thereafter 188,453 Total 235,028 Interest payments ( 128,166 ) Debt issuance costs ( 2,781 ) Total financing liability $ 104,081 Commitments — In July 2014, the Company entered into the Insulin Supply Agreement with Amphastar pursuant to which Amphastar manufactures for and supplies to the Company certain quantities of recombinant human insulin for use in Afrezza. Under the terms of the Insulin Supply Agreement, Amphastar is responsible for manufacturing the insulin in accordance with the Company’s specifications and agreed-upon quality standards. In May 2021, the Company and Amphastar amended the Insulin Supply Agreement to extend the term and restructure the annual purchase commitments. The Company's remaining purchase commitments were as follows (€ in millions): June 30, 2023 2023 4.8 2024 14.6 2025 15.5 2026 19.4 2027 9.2 Pursuant to the amendment, the term of the Insulin Supply Agreement expires on December 31, 2027 , unless terminated earlier, and can be renewed for additional, successive two-year terms upon 12 months’ written notice given prior to the end of the initial term or any additional two-year term. The Company and Amphastar each have normal and customary termination rights, including termination for a material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, the Company may terminate the Insulin Supply Agreement upon two years’ prior written notice to Amphastar without cause or upon 30 days’ prior written notice to Amphastar if a controlling regulatory authority withdraws approval for Afrezza, provided, however, in the event of a termination pursuant to either of the latter two scenarios, the provisions of the Insulin Supply Agreement require the Company to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination. Vehicle Leases — During the second quarter of 2018, the Company entered into a master lease agreement with Enterprise Fleet Management Inc. The monthly payment inclusive of maintenance fees, insurance and taxes is approximately $ 0.1 million. The lease expense is included in selling expenses in the condensed consolidated statements of operations. Office Leases — In May 2017, the Company executed an office lease with Russell Ranch Road II LLC for the Company’s corporate offices in Westlake Village, California, which was renewed in April 2022. Pursuant to the renewal, the monthly payments of $ 79,543 began in February 2023, subject to 3 % annual increases, plus the estimated cost of maintaining the property and common areas by the landlord, and further subject to a six-month base rent concession beginning February 2023. The Company is also entitled to a one-time allowance up to $ 0.9 million as reimbursement for tenant improvements or the purchase of furniture, fixtures or equipment. Of the $ 0.9 million allowance, an amount up to $ 0.7 million may be applied as an additional base rent concession. The Company has no further right to extend the lease term beyond July 31, 2028. In May 2022, the Company assumed certain leased real property (the “Marlborough Lease”) in connection with the V-Go acquisition. The Marlborough Lease pertains to certain premises in a building located in Marlborough, Massachusetts. The monthly payments of $ 28,895 began in June 2022, subject to approximately 3 % annual increases through February 28, 2026. The Company also acquired rights to a manufacturing service agreement where V-Go is manufactured using Company-owned equipment located at the manufacturing facility. The Company determined that this arrangement results in an embedded lease which granted the Company exclusive use of space within the manufacturing facility. The Company assessed the embedded lease cost to be $ 14,370 per month through February 28, 2026. Lease information was as follows (in thousands): June 30, 2023 December 31, 2022 Operating lease right-of-use assets (1) $ 5,329 $ 6,714 Operating lease liability-current (2) $ 944 $ 1,304 Operating lease liability-long-term 4,646 5,343 Total $ 5,590 $ 6,647 Weighted average remaining lease term (in years) 4.1 4.6 Weighted average discount rate 7.3 % 7.3 % _________________________ (1) Operating right-of-use assets related to vehicles, offices and the manufacturing facility are included in other assets in the condensed consolidated balance sheets. (2) Operating lease liability – current are included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. Three Months Six Months 2023 2022 2023 2022 Operating lease costs $ 410 $ 341 $ 831 629 Variable lease costs 13 73 49 159 Cash paid 234 446 557 887 The Company's future minimum office and vehicle lease payments were as follows (in thousands): June 30, 2023 2023 $ 441 2024 1,496 2025 1,861 2026 1,140 2027 1,072 Thereafter 643 Total 6,653 Interest expense ( 1,063 ) Total operating lease liability $ 5,590

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	16. Income Taxes Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and concluded, in accordance with the applicable accounting standards, that net deferred tax assets should be fully reserved. The Company has assessed its position with regards to uncertainty in tax positions and has not recognized a liability for unrecognized tax benefits. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. The Company recognizes interest and penalties accrued related to unrecognized tax benefits in income tax expense. During the six months ended June 30, 2023 , the Company did no t recognize any interest or penalties. The Company’s tax years since 2018 remain subject to examination by tax authorities.

Description of Business and S_2

Description of Business and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Business	Business — MannKind is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The Company’s signature technologies, Technosphere dry-powder formulations and Dreamboat inhalation devices, offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. The Company is currently commercializing Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. The first product to come out of the orphan lung disease pipeline, Tyvaso DPI (treprostinil) inhalation powder, received approval from the U.S. Food and Drug Administration (“FDA”) in May 2022 for the treatment of pulmonary arterial hypertension (PAH) and for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company's development and marketing partner, United Therapeutics ("UT") began commercializing Tyvaso DPI in June 2022 and is obligated to pay the Company a royalty on net sales of the product. The Company also receives a margin on supplies of Tyvaso DPI that it manufactures for UT.
Basis of Presentation	Basis of Presentation — The condensed consolidated financial statements have been prepared in accordance with GAAP.
Principles of Consolidation	Principles of Consolidation — The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.
Reclassifications	Reclassifications — Certain prior year reported amounts have been reclassified to conform with the current year presentation. Changes were made to the condensed consolidated statements of cash flows to present the amortization of debt discount and issuance costs separately and to disclose net investment accretion under other, net. In addition, changes were made to the condensed consolidated statements of operations to present selling expenses separately from general and administrative expenses.
Segment Information	Segment Information — Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as one segment operating in the United States of America.
Revenue Recognition	Revenue Recognition — The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC 606, including when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company has two types of contracts with customers: (i) contracts for commercial product sales with wholesale distributors, specialty and retail pharmacies and (ii) collaboration arrangements.
Revenue Recognition - Net Revenue - Commercial Product Sales	Revenue Recognition — Net Revenue – Commercial Product Sales — The Company sells its products to a limited number of wholesale distributors, specialty and retail pharmacies, and durable medical equipment suppliers (“DME”) in the U.S. (collectively, its “Customers”). Wholesale distributors subsequently resell the Company’s products to retail pharmacies and certain medical centers or hospitals. Specialty and retail pharmacies sell directly to patients. In addition to distribution agreements with Customers, the Company enters into arrangements with payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenue on product sales when the Customer obtains control of the Company's product, which occurs at delivery for wholesale distributors and generally at delivery for specialty pharmacies. The Company recognizes revenue on product sales to a retail pharmacy as the product is dispensed to patients. Product revenues are recorded net of applicable reserves, including discounts, allowances, rebates, returns and other incentives. See Reserves for Variable Consideration below. Free Goods Program — From time to time, the Company offers programs to potential new patients that allow them to obtain free goods (prescription fills) from a pharmacy. The Company excludes such amounts related to these programs from both gross and net revenue. The cost of product associated with the free goods program is recognized as cost of goods sold in the condensed consolidated statements of operations. Reserves for Variable Consideration — Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its Customers, payers, and other indirect customers relating to the Company’s sale of its products. These reserves, as further detailed below, are based on the amounts earned, or to be claimed on the related sales, and result in a reduction of accounts receivable or establishment of a current liability. Significant judgment is required in estimating gross-to-net adjustments, including historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, claim submission time lags and inventory levels in the distribution channel. Where appropriate, these estimates take into consideration a range of possible outcomes, which are probability-weighted in accordance with the expected value method in ASC 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reduce recognized revenue to the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analysis also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the current period estimates of gross-to-net adjustments and, therefore, the transaction price was not reduced further during the current period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net revenue from commercial product sales and earnings in the period such variances become known. Trade Discounts and Allowances — The Company generally provides Customers with discounts which include incentives, such as prompt pay discounts, that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its Customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company’s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of revenue and as a reduction to accounts receivable, net. Product Returns — Consistent with industry practice, the Company generally offers Customers a right of return for unopened product that has been purchased from the Company for a period beginning six months prior to and ending 12 months after its expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as reductions to accounts receivable, net. The Company currently estimates product returns using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company’s current return reserve percentage is estimated to be in the single digits. Adjustments to the returns reserve have been made in the past and may be necessary in the future based on revised estimates to the Company’s assumptions. Provider Chargebacks and Discounts — Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase products from the Company. Customers charge the Company for the difference between what they pay for products and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is recorded in accrued expenses and other current liabilities. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by Customers, and the Company generally issues credits for such amounts within a few weeks of the Customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, and chargebacks that Customers have claimed, but for which the Company has not yet issued a credit. Government Rebates — The Company is subject to discount obligations under Medicare and state Medicaid programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses and other current liabilities. Estimates around Medicaid have historically required significant judgment due to timing lags in receiving invoices for claims from states. For Afrezza, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for products that have been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. The Company’s estimates include consideration of historical claims experience, payer channel mix, current contract prices, unbilled claims, claim submission time lags and inventory in the distribution channel. Payer Rebates — The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates, including estimates for product that has been recognized as revenue, but which remains in the distribution channel, and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities. The Company’s estimates include consideration of historical claims experience, payer channel mix, current contract prices, unbilled claims, claim submission time lags and inventory in the distribution channel. Other Incentives — Other incentives which the Company offers include voluntary patient support programs, such as the Company's co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with co-payments required by payers. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with the products that have been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses and other current liabilities.
Revenue Recognition- Net Revenue - Collaborations and Services	Revenue Recognition — Revenue – Collaborations and Services — The Company enters into licensing, research or other agreements under which the Company licenses certain rights to its product candidates to third parties, conducts research or provides other services to third parties. The terms of these arrangements may include but are not limited to payment to the Company of one or more of the following: up-front license fees; development, regulatory, and commercial milestone payments; payments for commercial manufacturing and clinical supply services the Company provides; and royalties on net sales of licensed products and sublicenses of the rights. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment such as determining the performance obligation in the contract and determining the stand-alone selling price for each performance obligation identified in the contract. With respect to the Company's significant collaboration and service agreement with UT that includes a long-term commercial supply agreement (as amended, the “CSA”), the Company has identified three distinct performance obligations: (1) the license, supply of product to be used in clinical development, and continued development and approval support for Tyvaso DPI (“R&D Services and License”); (2) development activities for the next generation of the product (“Next-Gen R&D Services”); and (3) a material right associated with current and future manufacturing and supply of product (“Manufacturing Services”). Pre-production activities under the CSA, such as facility expansion services and other administrative services, were considered bundled services under the Manufacturing Services performance obligation as required by ASC 606. Following the FDA’s approval of Tyvaso DPI, UT began issuing purchase orders for the supply of product, which represents distinct contracts and performance obligations under ASC 606. Revenue is recognized for the supply of product at a point in time, once control is transferred to UT. See Note 10 – Collaboration, Licensing and Other Arrangements. If an arrangement has multiple performance obligations, the allocation of the transaction price is determined from observable market inputs, and the Company uses key assumptions to determine the stand-alone selling price, which may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success. Revenue is recognized based on the measurement of progress as the performance obligation is satisfied and consideration received that does not meet the requirements to satisfy the revenue recognition criteria is recorded as deferred revenue. Current deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. For further information, see Note 10 – Collaboration, Licensing and Other Arrangements. The Company recognizes upfront license payments as revenue upon delivery of the license only if the license is determined to be a separate unit of accounting from the other undelivered performance obligations. The undelivered performance obligations typically include manufacturing or development services or research and/or steering committee services. If the license is not considered as a distinct performance obligation, then the license and other undelivered performance obligations would be evaluated to determine if such should be accounted for as a single unit of accounting. If concluded to be a single performance obligation, the transaction price for the single performance obligation is recognized as revenue over the estimated period of when the performance obligation is satisfied. If the license is considered to be a distinct performance obligation, then the estimated revenue is included in the transaction price for the contract, which is then allocated to each performance obligation based on the respective standalone selling prices. Whenever the Company determines that an arrangement should be accounted for over time, the Company determines the period over which the performance obligations will be performed, and revenue will be recognized over the period the Company is expected to complete its performance obligations. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. The Company’s collaboration agreements typically entitle the Company to additional payments upon the achievement of development, regulatory and sales milestones. If the achievement of a milestone is considered probable at the inception of the collaboration, the related milestone payment is included with other collaboration consideration, such as upfront fees and research funding, in the Company’s revenue calculation. If these milestones are not considered probable at the inception of the collaboration, the milestones will typically be recognized in one of two ways depending on the timing of when the milestone is achieved. If the milestone is improbable at inception and subsequently deemed probable of achievement, such will be added to the transaction price, resulting in a cumulative adjustment to revenue. If the milestone is achieved after the performance period has been completed and all performance obligations have been delivered, the Company will recognize the milestone payment as revenue in its entirety in the period the milestone was achieved. The Company’s collaborative agreements, for accounting purposes, represent contracts with customers and therefore are not subject to accounting literature on collaborative agreements. The Company grants licenses to its intellectual property, supplies raw materials, semi-finished goods or finished goods, provides research and development services and offers sales support for the co-promotion of products, all of which are outputs of the Company’s ongoing activities, in exchange for consideration. Accordingly, the Company concluded that its collaborative agreements must generally be accounted for pursuant to ASC 606. For collaboration agreements that allow collaboration partners to select additional optioned products or services, the Company evaluates whether such options contain material rights (i.e., have exercise prices that are discounted compared to what the Company would charge for a similar product or service to a new collaboration partner). The exercise price of these options includes a combination of licensing fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, the Company concludes the option does not contain a material right, and therefore is not included in the transaction price at contract inception. The Company assessed the CSA agreement with UT and determined that a material right existed for the manufacturing services performance obligation. The transaction price is allocated to the material right as well as the remaining performance obligations in accordance with ASC 606. The Company also evaluates grants of additional licensing rights upon option exercises to determine whether such should be accounted for as separate contracts. Revenue Recognition – Royalties — The Company recognizes royalty revenue for a sales-based or usage-based royalty if it is promised in exchange for an intellectual property license. The royalty revenue is recognized as the latter of the subsequent sale of the product occurs or if the performance obligation to which the royalty has been allocated has been satisfied or partially satisfied. The Company’s collaborative agreement with UT entitles it to receive low double-digit royalties on net sales of Tyvaso DPI for the license of the Company’s IP that was considered to be interdependent with the development activities that supported the approval of Tyvaso DPI. The Company’s net revenue and cost of revenue and goods sold as shown on the condensed consolidated statement of operations is comprised of revenue generated from product sales, services and royalties as shown below (in thousands): Three Months Six Months 2023 2022 2023 2022 Net revenue: Product sales (1) $ 29,278 $ 17,417 $ 58,004 $ 28,427 Services (2) 278 1,173 500 2,155 Royalties (3) 19,055 304 30,733 304 Total net revenue $ 48,611 $ 18,894 $ 89,237 $ 30,886 _________________________ (1) Amounts represent the net sales of Afrezza and V-Go to wholesalers and specialty pharmacies and Tyvaso DPI to UT. (2) Amounts represent revenue generated from the Company's collaboration arrangements, including Next-Gen R&D Services (as defined in Note 10) for UT as well as arrangements with other collaboration partners. See Note 10 – Collaboration, Licensing and Other Arrangements . (3) Amounts represent royalties on UT’s net sales of Tyvaso DPI. Three Months Six Months 2023 2022 2023 2022 Cost of goods sold and cost of revenue: Product sales $ 13,995 $ 12,481 $ 30,023 $ 22,967 Services 242 434 427 946 Total cost of goods sold and cost of revenue $ 14,237 $ 12,915 $ 30,450 $ 23,913 The Company follows detailed accounting guidance in measuring revenue and certain judgments affect the application of its revenue policy. For example, in connection with its existing collaboration agreements, the Company has recorded on its condensed consolidated balance sheets short-term and long-term deferred revenue based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. However, this estimate is based on the Company’s current project development plan and, if the development plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12 -month period.
Milestone Payments	Milestone Payments — At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the customer, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as, or when, the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration, other revenue, and earnings in the period of adjustment.
Cost of Goods Sold	Cost of Goods Sold — Cost of goods sold includes material, labor costs and manufacturing overhead. Cost of goods sold also includes a component of current period manufacturing costs in excess of costs capitalized into inventory (“excess capacity costs”). These costs, in addition to the impact of the revaluation of inventory for standard costing, and write-offs of inventory are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. Cost of goods sold excludes the cost of insulin purchased under the Company’s Insulin Supply Agreement (the “Insulin Supply Agreement”) with Amphastar Pharmaceuticals, Inc. (“Amphastar”). All insulin inventory on hand was written off and the full purchase commitment contract to purchase future insulin was accrued as a recognized loss on purchase commitments as of the end of 2016.
Cost of Revenues	Cost of Revenues – Collaborations and Services — Cost of revenues for collaborations and services includes material, labor costs, manufacturing overhead, and excess capacity costs. These costs, in addition to the write-offs of inventory, are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. Cost of revenues for collaborations and services also includes the cost of product development.
Research and Development	Research and Development ("R&D") — Clinical trial expenses result from obligations under contracts with vendors, consultants and clinical site agreements in addition to internal costs associated with conducting clinical trials. R&D costs are expensed as incurred. Clinical study and certain research costs are recognized over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Nonrefundable advance payments for services to be received in the future for use in R&D activities are recorded as prepaid assets and expensed in the period when the services are performed.
Cash and Cash Equivalents	Cash and Cash Equivalents — The Company considers all highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase, that are readily convertible into cash to be cash equivalents. As of June 30, 2023 and December 31, 2022 , cash equivalents were comprised of money market funds, corporate bonds and commercial paper with original maturities less than 90 days from the date of purchase.
Held-to-Maturity Investments	Held-to-Maturity Investments — The Company’s investments generally consist of commercial paper, corporate notes or bonds and U.S. Treasury securities. As of June 30, 2023 and December 31, 2022, the Company held short-term and long-term investments of debt securities, including commercial paper and bonds. The Company assesses whether it has any intention to sell the investment before maturity, whether any declines in fair value are the result of credit losses, as well as whether there were other-than-temporary impairments associated with the available for sale investment. The Company intends to hold its investments until maturity; therefore, these investments are stated at amortized cost. The investments with maturities less than 12 months are included in short-term investments and investments with maturities in excess of twelve months are included in long-term investments in the condensed consolidated balance sheets. The amortization or accretion of the Company’s investments is recognized as interest income in the condensed consolidated statements of operations.
Available-for-Sale Investment	Available-for-Sale Investment — In June 2021, the Company purchased a $ 3.0 million convertible promissory note (the “Thirona convertible note”) issued by Thirona Bio, Inc. (“Thirona”). In January 2022, the Company purchased an additional $ 5.0 million convertible promissory note issued by Thirona. Unless earlier converted into conversion shares pursuant to the note purchase agreement, the principal and accrued interest shall be due and payable by Thirona on demand by the Company at any time after the maturity date. The Thirona convertible notes were amended in February 2023, which extended the maturity date from December 31, 2022 to June 30, 2024. The Thirona convertible notes are general unsecured obligations of Thirona and accrue interest at a rate of 6 % per annum. The Thirona convertible notes are classified as available-for-sale securities and are included in prepaid expenses and other current assets in the condensed consolidated balance sheets. The Company assesses whether it has any intention to sell the investment, determines fair value of its available-for-sale investments using level 3 inputs as well as assesses whether there were other-than-temporary impairments associated with the available-for-sale investment. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income until realized. In June 2021, the Company and Thirona also entered into a collaboration agreement to develop a compound for the treatment of fibrotic lung diseases. See Note 10 – Collaboration, Licensing and Other Arrangements .
Concentration of Credit Risk	Concentration of Credit Risk — Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and investments. Cash and cash equivalents are held in high credit quality institutions. Cash equivalents consist of interest-bearing money market funds and U.S. Treasury securities with original or remaining maturities of 90 days or less at the time of purchase. Investments generally consist of commercial paper, corporate notes or bonds and U.S. Treasury securities. The cash equivalents and investments are regularly monitored by management.
Accounts Receivable and Allowance for Credit Losses	Accounts Receivable and Allowance for Credit Losses — Accounts receivable are recorded at the invoiced amount and are not interest bearing. Accounts receivable are presented net of an allowance for credit losses if there are estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for credit losses. The allowance for expected credit losses is based primarily on past collections experience relative to the length of time receivables are past due. However, when available evidence reasonably supports an assumption that future economic conditions will differ from current and historical payment collections, an adjustment is reflected in the allowance for expected credit losses. Accounts receivable are also presented net of an allowance for product returns and trade discounts and allowances because the Company’s customers have the right of setoff for these amounts against the related accounts receivable.
Pre Launch Inventory	Pre-Launch Inventory — An improvement to the manufacturing process for the Company’s primary excipient, fumaryl diketopiperazine (“FDKP”) was demonstrated to be viable and management expects to realize an economic benefit in the future as a result of such process improvement. Accordingly, the Company is required to assess whether to capitalize inventory costs related to such excipient prior to regulatory approval of the new supplier and the improved manufacturing process. In doing so, management must consider a number of factors in order to determine the amount of inventory to be capitalized, including the historical experience of achieving regulatory approvals for the Company’s manufacturing process, feedback from regulatory agencies on the changes being effected and the amount of inventory that is likely to be used in commercial production. The shelf life of the excipient will be determined as part of the regulatory approval process; in the interim, the Company must assess the available stability data to determine whether there is likely to be adequate shelf life to support anticipated future sales occurring beyond the expected approval date of the new raw material. If management is aware of any specific material risks or contingencies other than the normal regulatory review and approval process, or if the criteria for capitalizing inventory produced prior to regulatory approval are otherwise not met, the Company would not capitalize such inventory costs, choosing instead to recognize such costs as R&D expense in the period incurred.
Inventories	Inventories — Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. The Company capitalizes inventory costs associated with the Company’s products based on management’s judgment that future economic benefits are expected to be realized; otherwise, such costs are expensed as incurred as cost of goods sold. The Company uses a contract manufacturing organization outside of the U.S. for certain stages of V-Go inventory. The Company periodically analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value and writes down such inventories, as appropriate. In addition, the Company’s products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or may become obsolete or are forecasted to become obsolete due to expiration, the Company will record a charge to write down such unmarketable inventory to its estimated net realizable value. The Company analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company performs an assessment of projected sales and evaluates the lower of cost or net realizable value and the potential excess inventory on hand at the end of each reporting period.
Property and equipment	Property and Equipment — Property and equipment is recorded at historical cost, net of accumulated depreciation. Depreciation expense is recorded over the assets’ useful lives on a straight-line basis. See Note 6 – Property and Equipment .
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets — Long-lived assets include property and equipment, operating lease right-of-use assets and other intangible assets. The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Assets are considered to be impaired if the carrying value is considered to be unrecoverable. If the Company believes an asset to be impaired, the impairment recognized is the amount by which the carrying value of the asset exceeds the fair value of the asset. Fair value is determined using the market, income or cost approaches as appropriate for the asset. Any write-downs are treated as permanent reductions in the carrying amount of the asset and recognized as an operating loss.
Acquisitions	Acquisitions — The Company first determines whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, the Company accounts for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process R&D (“IPR&D”) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in the Company’s condensed consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree’s liability arising from an acquisition it consummated prior to the Company’s acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&D projects with no alternative future use are recorded in R&D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2 – Acquisition .
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets — The fair value of acquired intangible assets is determined using an income-based approach referred to as the excess earnings method utilizing Level 3 fair value inputs. Market participant valuations assume a global view considering all potential jurisdictions and indications based on discounted after-tax cash flow projections, risk adjusted for estimated probability of technical and regulatory success. The Company tests for impairment annually on a reporting unit basis, at the beginning of the Company’s fourth fiscal quarter and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying amount. To the extent the carrying amount of a reporting unit is less than its estimated fair value, an impairment charge will be recorded. Finite-lived intangible assets are amortized on a straight-line basis over the estimated useful life. Estimated useful lives are determined considering the period assets are expected to contribute to future cash flows. Finite-lived intangible assets are tested for impairment when facts or circumstances suggest that the carrying value of the asset may not be recoverable. If the carrying value exceeds the projected undiscounted pretax cash flows of the intangible asset, an impairment loss equal to the excess of the carrying value over the estimated fair value (discounted after-tax cash flows) is recognized.
Recognized Loss on Purchase Commitments	Recognized Loss on Purchase Commitments — The Company assesses whether losses on long-term purchase commitments should be accrued. Losses that are expected to arise from firm, non-cancellable, commitments for the future purchases are recognized unless recoverable. When making the assessment, the Company also considers whether it is able to renegotiate with its vendors. The recognized loss on purchase commitments is reduced as inventory items are received. If, subsequent to an accrual, a purchase commitment is successfully renegotiated, the gain is recognized in the Company’s condensed consolidated statements of operations.
Milestone Rights Liability	Milestone Rights Liability — In July 2013, in conjunction with the execution of a (now repaid) loan agreement with Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, “Deerfield”), the Company entered into a Milestone Rights Purchase Agreement (the “Milestone Rights Agreement”) pursuant to which the Company issued certain milestone rights to Deerfield Private Design Fund II, L.P. and Horizon Santé FLML SÁRL (the “Original Milestone Purchasers”). The foregoing milestone rights provided the Original Milestone Purchasers certain rights to receive payments of up to $ 90.0 million upon the occurrence of specified strategic and Afrezza sales milestones, $ 60.0 million of which remains payable as of June 30, 2023 upon achievement of such milestones (collectively, the “Milestone Rights”). In December 2021, the Milestone Rights were purchased by Barings Global Special Situations Credit Fund 4 (Delaware), L.P. and Barings Global Special Situations Credit 4 (LUX) S.ar.l. (together the “Milestone Purchasers”). As a result, the Milestone Purchasers have assumed the obligations of the Original Milestone Purchasers and are now entitled to all rights under the Milestone Rights Agreement. The Milestone Rights liability is reported at fair value at the date of the agreement which is periodically offset against payments. See Note 11 – Fair Value of Financial Instruments . The initial fair value estimate of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones and discounted to present value using a selected market discount rate. The expected timing and probability of achieving the milestones was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. The Milestone Rights liability will be remeasured as the specified milestone events are achieved. Specifically, as each milestone event is achieved, the portion of the initially recorded Milestone Rights liability that pertains to the milestone event being achieved will be remeasured to the amount of the specified related milestone payment. The resulting change in the balance of the Milestone Rights liability due to remeasurement will be recorded in the Company’s condensed consolidated statements of operations as interest expense. Furthermore, the Milestone Rights liability will be reduced upon the settlement of each milestone payment. As a result, each milestone payment would be effectively allocated between a reduction of the recorded Milestone Rights liability and an expense representing a return on a portion of the Milestone Rights liability paid to the investor for the achievement of the related milestone event. As of June 30, 2023, a $ 5.0 million milestone rights payment was included in accrued expenses and other current liabilities in our condensed consolidated balance sheets, which will be paid in the third quarter of 2023. (See Note 8 – Accrued Expenses and Other Current Liabilities and Note 9 – Borrowings. )
Fair Value of Financial Instruments	Fair Value of Financial Instruments — The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 — Quoted prices for identical instruments in active markets. Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 — Significant inputs to the valuation model are unobservable.
Income Taxes	Income Taxes — The provisions for federal, foreign, state and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized. For uncertain tax positions, the Company determines whether it is “more likely than not” that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit can be recorded in the financial statements. For those tax positions where it is “not more likely than not” that a tax benefit will be sustained, no tax benefit is recognized. Penalties, if probable and reasonably estimable, are recognized as a component of income tax expense. The Company has reduced its deferred tax assets for uncertain tax positions but has not recorded liabilities for income tax expense, penalties, or interest.
Contingencies	Contingencies — The Company records a loss contingency for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These accruals represent management’s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may revise its estimates.
Stock-Based Compensation	Stock-Based Compensation — Share-based payments to employees, including grants of restricted stock units ("RSUs,") performance-based non-qualified stock options awards (“PNQs”), restricted stock units with market conditions (“Market RSUs”), options and the compensatory elements of employee stock purchase plans, are recognized in the condensed consolidated statements of operations based upon the fair value of the awards at the grant date. RSUs are valued based on the market price on the grant date. Market RSUs are valued using a Monte Carlo valuation model and RSUs with performance conditions are evaluated for the probability that the performance conditions will be met and estimates the date at which the performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period. The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee stock options and the compensatory elements of employee stock purchase plans.
Net Income (Loss) Per Share of Common Stock	Net Income (Loss) Per Share of Common Stock — Basic net income or loss per share excludes dilution for potentially dilutive securities and is computed by dividing net income or loss by the weighted average number of common shares outstanding during the period. Diluted net income or loss per share reflects the potential dilution under the treasury method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted net loss per share as they would be anti-dilutive.
Recently Issued Accounting Standards	Recently Issued Accounting Standards — From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s condensed consolidated financial position or results of operations upon adoption.

Description of Business and S_3

Description of Business and Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Revenue and Cost of Revenue and Goods Sold Generated From Product Sales, Services and Royalties	The Company’s net revenue and cost of revenue and goods sold as shown on the condensed consolidated statement of operations is comprised of revenue generated from product sales, services and royalties as shown below (in thousands): Three Months Six Months 2023 2022 2023 2022 Net revenue: Product sales (1) $ 29,278 $ 17,417 $ 58,004 $ 28,427 Services (2) 278 1,173 500 2,155 Royalties (3) 19,055 304 30,733 304 Total net revenue $ 48,611 $ 18,894 $ 89,237 $ 30,886 _________________________ (1) Amounts represent the net sales of Afrezza and V-Go to wholesalers and specialty pharmacies and Tyvaso DPI to UT. (2) Amounts represent revenue generated from the Company's collaboration arrangements, including Next-Gen R&D Services (as defined in Note 10) for UT as well as arrangements with other collaboration partners. See Note 10 – Collaboration, Licensing and Other Arrangements . (3) Amounts represent royalties on UT’s net sales of Tyvaso DPI. Three Months Six Months 2023 2022 2023 2022 Cost of goods sold and cost of revenue: Product sales $ 13,995 $ 12,481 $ 30,023 $ 22,967 Services 242 434 427 946 Total cost of goods sold and cost of revenue $ 14,237 $ 12,915 $ 30,450 $ 23,913

Acquisition (Tables)

Acquisition (Tables)	6 Months Ended
	Jun. 30, 2023
Business Acquisition [Line Items]
Summary of Supplemental Pro Forma Information (Unaudited)	The following unaudited pro forma summary presents consolidated information of the Company as if the acquisition had occurred on January 1, 2022 (in thousands): Three Months Six Months 2023 2022 2023 2022 Net revenue $ 48,611 $ 24,992 $ 89,237 $ 43,082 Net loss ( 5,265 ) ( 28,763 ) ( 15,060 ) ( 54,505 ) Net loss per share - basic and diluted ( 0.02 ) ( 0.11 ) ( 0.06 ) ( 0.22 )
V-Go
Business Acquisition [Line Items]
Schedule of Purchase Consideration	The total purchase consideration for V-Go was as follows (in thousands): Fair value of consideration: Amount Cash consideration $ 15,341 Fair value of contingent consideration (1) 610 Total $ 15,951 ____________________________ (1) Subsequent changes in the fair value are reported in general and administrative expenses. As of June 30, 2023, the fair value of the contingent milestone liability was $ 0.6 million. The fair value of the contingent milestone liability as of December 31, 2022 was consistent with the fair value on the acquisition date.
Schedule of Preliminary Amounts of Identifiable Assets Acquired and Liabilities Assumed	The information below reflects the amounts of identifiable assets acquired and liabilities assumed as of May 31, 2023 (in thousands): Amount Assets: Inventory (1) $ 11,152 Property and equipment 2,921 Goodwill (1) 1,931 Intangible asset - Developed technology 1,200 Operating lease right-of-use assets 1,812 Total assets 19,016 Liabilities: Liabilities assumed (1) 1,253 Operating lease liability 1,812 Total liabilities 3,065 Net assets acquired $ 15,951 ___________________________ (1) Through May 2023, goodwill related to the acquisition of V-Go was adjusted for a reduction in rebate-related liabilities partially offset by a reserve for inventory obsolescence.

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2023
Schedule of Investments [Abstract]
Schedule of Contractual Maturities of Held to Maturity Investments	The contractual maturities of the Company’s held to maturity investments are summarized below (in thousands): June 30, 2023 December 31, 2022 Amortized Aggregate Amortized Aggregate Due in one year or less (1) $ 133,088 $ 132,864 $ 152,862 $ 156,976 Due after one year through five years 2,282 2,258 1,961 1,948 Total $ 135,370 $ 135,122 $ 154,823 $ 158,924 ___________________________ (1) The investments due in one year or less include cash equivalents of $ 74.9 million as of June 30, 2023 and $ 51.8 million as of December 31, 2022.
Schedule of Fair Value of Cash Equivalents, Long and Short Term Investments	The fair value of the cash equivalents, long-term and short-term investments are disclosed below (dollars in thousands). June 30, 2023 Investment Level Amortized Cost Gross Unrealized Estimated Commercial bonds and paper Level 2 $ 46,369 $ ( 108 ) $ 46,261 Money market funds Level 1 73,479 6 73,485 U.S. Treasuries Level 2 15,522 ( 146 ) 15,376 Total cash equivalents and investments 135,370 ( 248 ) 135,122 Less: cash equivalents 74,925 — 74,925 Total Investments $ 60,445 $ ( 248 ) $ 60,197 December 31, 2022 Investment Level Amortized Cost Gross Unrealized Estimated Commercial bonds and paper Level 2 $ 66,762 $ ( 594 ) $ 66,168 Money market funds Level 1 51,783 — 51,783 U.S. Treasuries Level 2 36,278 ( 587 ) 35,691 Total cash equivalents and investments 154,823 ( 1,181 ) 153,642 Less: cash equivalents 51,783 — 51,783 Total Investments $ 103,040 $ ( 1,181 ) $ 101,859

Accounts Receivable (Tables)

Accounts Receivable (Tables)	6 Months Ended
	Jun. 30, 2023
Receivables [Abstract]
Schedule of Accounts Receivable, Net	Accounts receivable, net consists of the following (in thousands): June 30, 2023 December 31, 2022 Accounts receivable – commercial Accounts receivable, gross $ 20,078 $ 19,359 Wholesaler distribution fees and prompt pay discounts ( 3,319 ) ( 2,536 ) Reserve for returns ( 4,316 ) ( 4,108 ) Total accounts receivable – commercial, net 12,443 12,715 Accounts receivable – collaborations and services 15,346 4,086 Total accounts receivable, net $ 27,789 $ 16,801

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Components of Inventory	Inventories consist of the following (in thousands): June 30, 2023 December 31, 2022 Raw materials $ 5,859 $ 5,739 Work-in-process 10,698 13,815 Finished goods 8,733 2,218 Total inventory $ 25,290 $ 21,772

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and equipment consists of the following (dollars in thousands): Estimated Useful Life (Years) June 30, 2023 December 31, 2022 Land — $ 875 $ 875 Buildings 39 - 40 17,389 17,389 Building improvements 5 - 40 43,527 38,952 Machinery and equipment 3 - 15 58,905 58,542 Furniture, fixtures and office equipment 5 - 10 2,976 2,976 Computer equipment and software 3 8,646 8,246 Construction in progress — 37,412 16,706 Total property and equipment 169,730 143,686 Less accumulated depreciation ( 100,220 ) ( 98,560 ) Total property and equipment, net $ 69,510 $ 45,126
Depreciation Expense Related to Property and Equipment	Depreciation expense related to property and equipment was as follows (in thousands): Three Months Six Months 2023 2022 2023 2022 Depreciation Expense $ 1,095 $ 727 $ 2,133 $ 1,326

Goodwill and Other Intangible_2

Goodwill and Other Intangible Asset (Tables)	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Other Intangible Asset	Other Intangible Asset — Other intangible asset consisted of the following (dollars in thousands): Estimated June 30, 2023 December 31, 2022 Useful Cost Accumulated Net Book Value Cost Accumulated Net Book Value Developed technology 15 $ 1,200 $ ( 87 ) $ 1,113 $ 1,200 $ ( 47 ) $ 1,153

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities were comprised of the following (in thousands): June 30, 2023 December 31, 2022 Salary and related expenses $ 12,140 $ 14,906 Discounts and allowances for commercial product sales 10,153 8,504 Accrued interest (1) 6,267 2,201 Current portion of milestone rights liability (2) 1,676 924 Deferred lease liability 944 1,304 Professional fees 818 1,136 Returns reserve for acquired product 633 1,013 Danbury facility buildout 93 846 Other 4,109 4,719 Accrued expenses and other current liabilities $ 36,833 $ 35,553 _________________________ (1) As of June 30, 2023, accrued interest includes $ 4.1 million related to a milestone payment of $ 5.0 million to be paid in the third quarter of 2023. (2) As of June 30, 2023, the current portion of milestone rights liability includes $ 0.9 million to be paid in the third quarter of 2023 and $ 0.8 million reclassed from long-term to short-term milestone right liability.

Borrowings (Tables)

Borrowings (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Summary of Carrying Amount of Borrowings	Carrying amount of the Company's borrowings consist of the following (in thousands): June 30, 2023 December 31, 2022 Senior convertible notes $ 226,124 $ 225,397 MidCap credit facility 39,478 39,264 Mann Group convertible note 8,829 8,829 Total debt – net carrying amount $ 274,431 $ 273,490
Schedule of Line of Credit Facility Debt and Key Terms	The following table provides a summary of the Company’s principal balance of debt and key terms: Amount Due Terms June 30, 2023 December 31, 2022 Annual Interest Maturity Date Conversion Price Senior convertible notes $ 230.0 million $ 230.0 million 2.50 % March 2026 $ 5.21 MidCap credit facility (1) $ 40.0 million $ 40.0 million one-month 1 % floor) 6.25 %; 8.25 % (1 ) August 2025 (1 ) N/A Mann Group convertible note $ 8.8 million $ 8.8 million 2.50 % December 2025 $ 2.50 _________________________ (1) In August 2022, the Company amended the MidCap credit facility and transitioned the benchmark interest rate from LIBOR to the Secured Overnight Financing Rate (“SOFR”).
Schedule of Maturities of Company's Borrowings	The maturities of the Company’s borrowings as of June 30, 2023 are as follows (in thousands): Amounts 2023 $ 6,667 2024 20,000 2025 22,163 2026 230,000 Total principal payments 278,830 Unamortized discount ( 521 ) Debt issuance costs ( 3,878 ) Total debt $ 274,431
Schedule of Amortization of Premium and Accretion of Debt Issuance Costs	Amortization of the premium and accretion of debt issuance costs related to all borrowings were as follows (in thousands): Three Months Six Months 2023 2022 2023 2022 Amortization of debt discount $ 108 $ 106 $ 214 $ 212 Amortization of debt issuance cost 363 363 727 726

Collaboration, Licensing and _2

Collaboration, Licensing and Other Arrangements (Tables)	6 Months Ended
	Jun. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Schedule of Revenue from Collaboration and Services	Revenue from collaborations and services were as follows (in thousands): Three Months Six Months 2023 2022 2023 2022 UT CSA Agreement (1) $ 10,933 $ 4,695 $ 22,097 $ 5,879 UT License Agreement (2) 242 698 427 1,556 Cipla License and Distribution Agreement 36 36 73 73 Vertice Pharma Co-Promotion Agreement — 325 — 325 Other — 114 — 201 Total revenue from collaborations and services $ 11,211 $ 5,868 $ 22,597 $ 8,034 _________________________ (1) Amount consists of revenue recognized for Manufacturing Services and sales of product to UT for the periods presented. (2) Amounts consist of revenue recognized for Next-Gen R&D Services and R&D Services and License for the periods presented.
Schedule of Effect of Modification on Transaction Price	The Company determined that the capital and continuous improvements should be combined with the manufacturing services performance obligation and the alternative manufacturing processes should be combined with the Next-Gen R&D Services. The total revised anticipated cash flows of $ 722.3 million from the transaction was allocated to the three distinct performance obligations as follows (dollars in millions): Anticipated Cash Flow Revenue Allocation Recognition Method Progress Measure Revenue Total anticipated cash flow (1) $ 722.3 Distinct Performance Obligation R&D Services and License $ — Over time Ratably Aug 2021 - Oct 2021 Next-Gen R&D Services $ 10.0 Over time Input % of completion of costs Manufacturing Services and (2) $ 712.3 Point in time Transfer of control __________________________ (1) The total anticipated cash flow includes a transaction price of $ 120.0 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $ 602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA. (2) The Manufacturing Services performance obligation will be recognized as control of manufactured products is transferred to UT. The modification did not result in a cumulative catch-up adjustment as a result of the revenue being deferred for the performance obligations that were affected by the modification. The allocation of the transaction price for the Manufacturing Services includes a material right related to the Company’s estimated production of product in the amount of $ 220.8 million. The Company will sell product to UT under individual purchase orders, which represent distinct performance obligations. The ultimate cash flows may vary as manufacturing purchase orders are received.
United Therapeutics Corporation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Schedule of Revenue from Collaboration and Services	Total revenue from UT was as follows (in thousands): Three Months Six Months 2023 2022 2023 2022 UT Revenue UT CSA Agreement $ 10,933 $ 4,695 $ 22,097 $ 5,879 UT License Agreement 242 698 427 1,556 Royalties — Collaborations (1) 19,055 304 30,733 304 Total revenue from UT $ 30,230 $ 5,697 $ 53,257 $ 7,739 _________________________ (1) Amount consists of royalties associated with the UT License Agreement. The contract assets related to the royalties is included in prepaid expense and other current assets in the condensed consolidated balance sheets.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	The following tables set forth the fair value of the Company’s financial instruments (in thousands): June 30, 2023 Fair Value Carrying Amount Significant Financial liabilities: Senior convertible notes (1) $ 226,124 $ 241,904 MidCap credit facility (2) 39,478 41,721 Mann Group convertible note (3) 8,829 16,316 Milestone rights (4) 4,838 11,800 Contingent milestone liability (4) 610 610 Financing liability (5) 104,081 103,229 _________________________ (1) Fair value was determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 11 %, volatility of 72.9 % and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or – 2 % would result in a fair value of $ 233.4 million and $ 250.9 million, respectively. (2) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 12 %. A change in yield of + or – 2 % would result in a fair value of $ 40.9 million and $ 42.6 million, respectively. (3) The fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 13 % and volatility of 72.3 % to the straight note and a binomial option pricing model for the value of the conversion feature. A change in yield of + or – 2 % would result in a fair value of $ 16.0 million and $ 16.6 million, respectively. (4) Fair value was determined by applying a Monte Carlo simulation. (5) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 10 %. December 31, 2022 Fair Value Carrying Value Significant Financial liabilities: Senior convertible notes (1) $ 225,397 $ 253,864 MidCap credit facility (2) 39,264 41,070 Mann Group convertible note (3) 8,829 20,836 Milestone rights (4) 4,838 12,600 Contingent milestone liability (4) 610 960 Financing liability (5) 104,077 103,239 _________________________ (1) Fair value was determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 13 %, volatility of 75.8 % and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or – 2 % would result in a fair value of $ 245.0 million and $ 263.4 million, respectively. (2) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 12 %. A change in yield of + or – 2 % would result in a fair value of $ 40.0 million and $ 42.4 million, respectively. (3) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 13 % and volatility of 77.8 % to the straight note and a binomial option pricing model for the value of the conversion feature. A change in yield of + or – 2 % would result in a fair value of $ 20.5 million and $ 21.2 million, respectively. (4) Fair value was determined by applying a Monte Carlo simulation. (5) Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 10 %.

Earnings Per Common Share ("E_2

Earnings Per Common Share ("EPS") (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Components of Basic and Diluted EPS Computations	The following tables summarize the components of the basic and diluted EPS computations (in thousands, except per share amounts): Three Months Six Months 2023 2022 2023 2022 EPS — basic and diluted: Net loss (numerator) $ ( 5,265 ) $ ( 29,023 ) $ ( 15,060 ) $ ( 55,021 ) Weighted average common shares (denominator) 265,626 253,644 264,802 252,775 Net loss per share $ ( 0.02 ) $ ( 0.11 ) $ ( 0.06 ) $ ( 0.22 )
Potential Dilutive Securities Outstanding that are Considered Antidilutive	Potentially dilutive securities outstanding that are considered antidilutive are summarized as follows (in shares): Six Months 2023 2022 Senior convertible notes 44,120,463 44,120,463 RSUs and Market RSUs (1) 16,951,734 15,848,183 Common stock options and PNQs 8,688,625 9,766,028 Mann Group convertible notes 3,370,000 3,370,000 Employee stock purchase plan — 235,794 Total shares 73,130,822 73,340,468 __________________________ (1) Market RSUs issued in 2021, 2022, and 2023 are included at the share delivery of 0 %, 162 %, and 100 %, respectively, in accordance with a valuation assessment obtained as of June 30, 2023 .

Stock-Based Compensation Expe_2

Stock-Based Compensation Expense (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Employee Awards and Non-employee Director Award Plan Activity	During the six months ended June 30, 2023, the Company granted the following awards (in shares): Three Months Three Months Six Months 2023 2023 2023 Employee awards: RSUs 179,905 (1) 2,660,721 (2) 2,840,626 Market RSUs — 1,445,000 (3) 1,445,000 Non-employee director RSUs — 319,904 (4) 319,904 Total awards issued 179,905 4,425,625 4,605,530 _________________________ (1) RSUs had a weighted average grant date fair value of $ 4.16 per share, of which 91,900 RSUs had a cliff vesting period of three years , 42,000 RSUs had a cliff vesting period of two years , and 46,005 RSUs had a vesting period of 25 % annually over four years . (2) RSUs had a weighted average grant date fair value of $ 4.56 per share, of which 2,598,971 RSUs had a vesting period of 25 % annually over four years , and 61,750 RSUs had a cliff vesting period of 3 years . (3) Market RSUs had a grant date fair value of $ 9.40 per share and will vest on July 15, 2026 provided the closing price of the Company’s common stock on June 30, 2026 is not less than the closing price on July 1, 2023. The number of shares delivered on the vesting date is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until July 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile= 0 % of target, 25th percentile= 50 % of target, 50th percentile= 100 % of target, 75th percentile= 200 % of target, 90th percentile or higher= 300 % maximum. Payout values will be interpolated between the percentile rankings above. (4) RSUs had a weighted average grant date fair value of $ 4.55 per share and vested immediately upon the grant date; however, the underlying shares of common stock will not be delivered until there is a separation of service such as resignation, retirement or death.
Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations	Total stock-based compensation expense recognized in the condensed consolidated statements of operations as cost of goods sold, cost of revenue – collaborations and services, R&D, selling and general and administrative expense was as follows (in thousands): Three Months Six Months 2023 2022 2023 2022 RSUs and options $ 5,404 $ 4,239 $ 8,882 $ 6,883 Employee stock purchase plan 176 183 353 345 Total $ 5,580 $ 4,422 $ 9,235 $ 7,228

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Lease Term and Discount Rate	Financing liability information was as follows: June 30, 2023 December 31, 2022 Weighted average remaining lease term (in years) 18.3 18.8 Weighted average discount rate 9.0 % 9.0 % Lease information was as follows (in thousands): June 30, 2023 December 31, 2022 Operating lease right-of-use assets (1) $ 5,329 $ 6,714 Operating lease liability-current (2) $ 944 $ 1,304 Operating lease liability-long-term 4,646 5,343 Total $ 5,590 $ 6,647 Weighted average remaining lease term (in years) 4.1 4.6 Weighted average discount rate 7.3 % 7.3 % _________________________ (1) Operating right-of-use assets related to vehicles, offices and the manufacturing facility are included in other assets in the condensed consolidated balance sheets. (2) Operating lease liability – current are included in accrued expenses and other current liabilities in the condensed consolidated balance sheets.
Summary of Lease Information	Three Months Six Months 2023 2022 2023 2022 Interest expense on financing liability $ 2,449 $ 2,443 $ 4,873 $ 4,814 Three Months Six Months 2023 2022 2023 2022 Operating lease costs $ 410 $ 341 $ 831 629 Variable lease costs 13 73 49 159 Cash paid 234 446 557 887
Summary of Remaining Financing Liability Payments	The Company's remaining financing liability payments were as follows (in thousands): June 30, 2023 2023 $ 4,906 2024 10,018 2025 10,269 2026 10,533 2027 10,849 Thereafter 188,453 Total 235,028 Interest payments ( 128,166 ) Debt issuance costs ( 2,781 ) Total financing liability $ 104,081
Remaining Purchase Requirements	In May 2021, the Company and Amphastar amended the Insulin Supply Agreement to extend the term and restructure the annual purchase commitments. The Company's remaining purchase commitments were as follows (€ in millions): June 30, 2023 2023 4.8 2024 14.6 2025 15.5 2026 19.4 2027 9.2
Schedule of Future Minimum Office And Vehicle Lease Payments	The Company's future minimum office and vehicle lease payments were as follows (in thousands): June 30, 2023 2023 $ 441 2024 1,496 2025 1,861 2026 1,140 2027 1,072 Thereafter 643 Total 6,653 Interest expense ( 1,063 ) Total operating lease liability $ 5,590

Description of Business and S_4

Description of Business and Significant Accounting Policies - Additional Information (Detail)		1 Months Ended			6 Months Ended
		Jan. 31, 2022 USD ($)	Jun. 30, 2021 USD ($)	Apr. 30, 2021 USD ($)	Jun. 30, 2023 USD ($) Segment	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Jul. 01, 2013 USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Accumulated deficit					$ (3,232,529,000)		$ (3,217,469,000)
Cash and cash equivalents					86,184,000		69,767,000
Short-term investments					58,163,000		101,079,000
Long-term investments					2,282,000		1,961,000
Financing liability					$ 104,100,000		104,100,000
Number of operating segment | Segment					1
Purchase of available-for-sale investment						$ 5,000,000
Milestone Rights Payment					$ 5,000,000
Maximum | AFREZZA product sales
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sales return right following product expiration in months					12 months
Minimum | AFREZZA product sales
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sales return right following product expiration in months					6 months
Convertible Promissory Note | Thirona Bio, Inc.
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Purchase of available-for-sale investment		$ 5,000,000	$ 3,000,000
Interest rate					6%
MidCap Credit Facility
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Principal amount	[1]				$ 40,000,000		$ 40,000,000
Principal prepayment against outstanding term loans				$ 10,000,000
MidCap Credit Facility | Tranche Three
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Amount available under credit facility				$ 60,000,000	60,000,000			$ 25,000,000
Milestone Rights Liability | Deerfield
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Contingent liability remain payable					$ 60,000,000				$ 60,000,000
Milestone Rights Liability | Maximum | Deerfield
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Contingent liability for milestone payments									$ 90,000,000
[1] In August 2022, the Company amended the MidCap credit facility and transitioned the benchmark interest rate from LIBOR to the Secured Overnight Financing Rate (“SOFR”).

Description of Business and S_5

Description of Business and Significant Accounting Policies - Additional Information (Detail 1)	Jun. 30, 2023
Collaborations and services | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-07-01
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Remaining performance obligation, expected timing of satisfaction, period	12 months

Description of Business and S_6

Description of Business and Significant Accounting Policies - Summary of Revenue and Cost of Revenue and Goods Sold Generated From Product Sales, Services and Royalties (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation Of Revenue [Line Items]
Total net revenue	$ 48,611	$ 18,894	$ 89,237	$ 30,886
Total cost of goods sold and cost of revenue	14,237	12,915	30,450	23,913
Product Sales
Disaggregation Of Revenue [Line Items]
Total net revenue	29,278	17,417	58,004	28,427
Total cost of goods sold and cost of revenue	13,995	12,481	30,023	22,967
Services
Disaggregation Of Revenue [Line Items]
Total net revenue	278	1,173	500	2,155
Total cost of goods sold and cost of revenue	242	434	427	946
Royalty collaborations
Disaggregation Of Revenue [Line Items]
Total net revenue	$ 19,055	$ 304	$ 30,733	$ 304

Acquisition - Additional Inform

Acquisition - Additional Information (Detail)		3 Months Ended		6 Months Ended
	May 31, 2022 USD ($) yr	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	May 31, 2023 USD ($)	[1]	Dec. 31, 2022
Business Acquisition [Line Items]
Incremental borrowing rate	7.25%	7.30%		7.30%				7.30%
V-Go
Business Acquisition [Line Items]
Inventory	$ 11,200,000					$ 11,152,000
Acquisition-related costs		$ 0		$ 0
Net revenue		4,800,000	$ 2,100,000	10,000,000	$ 2,100,000
Loss from operations		$ 500,000	$ 300,000	$ 1,500,000	$ 300,000
V-Go | Risk-Free Rate
Business Acquisition [Line Items]
Measurement inputs	0.0392
V-Go | Dividend Yield
Business Acquisition [Line Items]
Measurement inputs	0
V-Go | Volatility
Business Acquisition [Line Items]
Measurement inputs	0.43
V-Go | Period
Business Acquisition [Line Items]
Measurement inputs | yr	15
V-Go | Credit Risk
Business Acquisition [Line Items]
Measurement inputs	0.17
V-Go
Business Acquisition [Line Items]
Asset acquisition, date of acquisition agreement	May 31, 2022
Asset acquisition, up-front consideration	$ 15,341,000
Goodwill amortization period	15 years
V-Go | Maximum
Business Acquisition [Line Items]
Sales-based milestone payments payable	$ 10,000,000
Annual revenue milestones ranges for milestone payments	100,000,000
V-Go | Minimum
Business Acquisition [Line Items]
Annual revenue milestones ranges for milestone payments	$ 40,000,000
[1] Through May 2023, goodwill related to the acquisition of V-Go was adjusted for a reduction in rebate-related liabilities partially offset by a reserve for inventory obsolescence.

Acquisition - Schedule of Purch

Acquisition - Schedule of Purchase Consideration (Detail) - V-Go $ in Thousands	May 31, 2022 USD ($)
Fair value of consideration:
Cash consideration	$ 15,341
Fair value of contingent consideration	610	[1]
Total	$ 15,951
[1] Subsequent changes in the fair value are reported in general and administrative expenses. As of June 30, 2023, the fair value of the contingent milestone liability was $ 0.6 million. The fair value of the contingent milestone liability as of December 31, 2022 was consistent with the fair value on the acquisition date.

Acquisition - Schedule of Pur_2

Acquisition - Schedule of Purchase Consideration (Parenthetical) (Details) $ in Millions	Jun. 30, 2023 USD ($)
V-Go
Business Acquisition [Line Items]
Contingent milestone liability	$ 0.6

Acquisition - Schedule of Preli

Acquisition - Schedule of Preliminary Amounts of Identifiable Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands		Jun. 30, 2023	May 31, 2023		Dec. 31, 2022	May 31, 2022
Assets:
Goodwill		$ 1,931			$ 2,428
V-Go
Assets:
Inventory			$ 11,152	[1]		$ 11,200
Property and equipment			2,921
Goodwill	[1]		1,931
Intangible asset - Developed technology			1,200
Operating lease right-of-use assets			1,812
Total assets			19,016
Liabilities:
Liabilities assumed	[1]		1,253
Operating lease liability			1,812
Total liabilities			3,065
Net assets acquired			$ 15,951
[1] Through May 2023, goodwill related to the acquisition of V-Go was adjusted for a reduction in rebate-related liabilities partially offset by a reserve for inventory obsolescence.

Acquisition - Summary of Supple

Acquisition - Summary of Supplemental Pro Forma Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Business Acquisition, Pro Forma Information [Abstract]
Net revenue	$ 48,611	$ 24,992	$ 89,237	$ 43,082
Net loss	$ (5,265)	$ (28,763)	$ (15,060)	$ (54,505)
Net loss per share - basic	$ (0.02)	$ (0.11)	$ (0.06)	$ (0.22)
Net loss per share - diluted	$ (0.02)	$ (0.11)	$ (0.06)	$ (0.22)

Investments - Additional Inform

Investments - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Schedule Of Investments [Line Items]
Interest on available for sale investment	$ 100,000	$ 100,000	$ 200,000	$ 200,000
Interest on held to maturity investments	1,000,000	500,000	2,200,000	900,000
Amortization on investments	400,000	$ 200,000	400,000	$ 500,000
Allowance for credit losses	0		0
Accrued interest receivable					$ 600,000
Amount receivable on matured investment					5,100,000
Prepaid Expenses and Other Current Assets
Schedule Of Investments [Line Items]
Investment securities	200,000		200,000
Amount receivable on matured investment	200,000		200,000
Convertible Promissory Note | Thirona Bio, Inc.
Schedule Of Investments [Line Items]
Investment securities	8,400,000		8,400,000		$ 7,100,000
Gain on available for sale investment	900,000		900,000
Unrealized holding gain	$ 400,000		$ 400,000

Investments - Schedule of Contr

Investments - Schedule of Contractual Maturities of Held to Maturity Investments (Detail) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Debt Securities, Held-to-Maturity, Maturity [Abstract]
Amortized cost basis, due in one year or less	[1]	$ 133,088	$ 152,862
Amortized cost basis due after one year through five years		2,282	1,961
Amortized cost basis, total		135,370	154,823
Aggregate fair value, due in one year or less	[1]	132,864	156,976
Aggregate fair value, due after one year through five years		2,258	1,948
Aggregate fair value, total		$ 135,122	$ 158,924
[1] The investments due in one year or less include cash equivalents of $ 74.9 million as of June 30, 2023 and $ 51.8 million as of December 31, 2022.

Investments - Schedule of Con_2

Investments - Schedule of Contractual Maturities of Held to Maturity Investments (Parenthetical) (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Schedule of Held-to-Maturity Securities [Line Items]
Cash and cash equivalents	$ 86,184	$ 69,767
Due in One Year or Less
Schedule of Held-to-Maturity Securities [Line Items]
Cash and cash equivalents	$ 74,900	$ 51,800

Investments - Schedule of Fair

Investments - Schedule of Fair Value of Cash Equivalents, Long and Short Term Investments (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Amortized Cost
Schedule Of Investments [Line Items]
Total cash equivalents and investments	$ 135,370	$ 154,823
Less cash equivalents	74,925	51,783
Total Investments	(60,445)	(103,040)
Amortized Cost | Commercial Bonds and Paper | Fair Value, Inputs, Level 2
Schedule Of Investments [Line Items]
Total cash equivalents and investments	46,369	66,762
Amortized Cost | Money Market Funds | Fair Value, Inputs, Level 1
Schedule Of Investments [Line Items]
Total cash equivalents and investments	73,479	51,783
Amortized Cost | U.S. Treasuries | Fair Value, Inputs, Level 2
Schedule Of Investments [Line Items]
Total cash equivalents and investments	15,522	36,278
Gross Unrealized Holding Gains (Losses)
Schedule Of Investments [Line Items]
Total cash equivalents and investments	(248)	(1,181)
Total Investments	(248)	(1,181)
Gross Unrealized Holding Gains (Losses) | Commercial Bonds and Paper | Fair Value, Inputs, Level 2
Schedule Of Investments [Line Items]
Total cash equivalents and investments	(108)	(594)
Gross Unrealized Holding Gains (Losses) | Money Market Funds | Fair Value, Inputs, Level 1
Schedule Of Investments [Line Items]
Total cash equivalents and investments	6
Gross Unrealized Holding Gains (Losses) | U.S. Treasuries | Fair Value, Inputs, Level 2
Schedule Of Investments [Line Items]
Total cash equivalents and investments	(146)	(587)
Estimated Fair Value
Schedule Of Investments [Line Items]
Total cash equivalents and investments	135,122	153,642
Less cash equivalents	74,925	51,783
Total Investments	(60,197)	(101,859)
Estimated Fair Value | Commercial Bonds and Paper | Fair Value, Inputs, Level 2
Schedule Of Investments [Line Items]
Total cash equivalents and investments	46,261	66,168
Estimated Fair Value | Money Market Funds | Fair Value, Inputs, Level 1
Schedule Of Investments [Line Items]
Total cash equivalents and investments	73,485	51,783
Estimated Fair Value | U.S. Treasuries | Fair Value, Inputs, Level 2
Schedule Of Investments [Line Items]
Total cash equivalents and investments	$ 15,376	$ 35,691

Schedule of Accounts Receivable

Schedule of Accounts Receivable, Net (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Accounts Receivable [Line Items]
Total accounts receivable, net	$ 27,789	$ 16,801
Commercial product sales
Accounts Receivable [Line Items]
Accounts receivable, gross	20,078	19,359
Wholesaler distribution fees and prompt pay discounts	(3,319)	(2,536)
Reserve for returns	(4,316)	(4,108)
Total accounts receivable, net	12,443	12,715
Collaborations and services
Accounts Receivable [Line Items]
Total accounts receivable, net	$ 15,346	$ 4,086

Accounts Receivable - Additiona

Accounts Receivable - Additional Information (Detail)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2023 USD ($) Distributor	Dec. 31, 2022 USD ($) Distributor
Accounts Receivable [Line Items]
Number of wholesale distributors | Distributor		3	3
Percentage of gross sales from major wholesale distributors	71%	71%
Allowance for credit losses for accounts receivable | $	$ 0	$ 0	$ 0
Percentage of revenue from major customers collaborations and services	100%	100%
United Therapeutics Corporation
Accounts Receivable [Line Items]
Percentage of collaborations and services net accounts receivables		100%	100%
Commercial product sales
Accounts Receivable [Line Items]
Percentage of accounts receivable from major wholesale distributors	78%	78%	79%

Inventories - Components of Inv

Inventories - Components of Inventory (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 5,859	$ 5,739
Work-in-process	10,698	13,815
Finished goods	8,733	2,218
Total inventory	$ 25,290	$ 21,772

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Inventory [Line Items]
Inventory write-offs	$ 1,000	$ 500	$ 3,359	$ 451
Pre-launch Inventory
Inventory [Line Items]
Raw materials inventory	$ 800		$ 800		$ 800

Property and Equipment, Net (De

Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 169,730	$ 143,686
Less accumulated depreciation	(100,220)	(98,560)
Total property and equipment, net	69,510	45,126
Land
Property Plant And Equipment [Line Items]
Property and equipment - gross	875	875
Buildings
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 17,389	17,389
Buildings | Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	39 years
Buildings | Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	40 years
Building Improvements
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 43,527	38,952
Building Improvements | Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	5 years
Building Improvements | Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	40 years
Machinery and Equipment
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 58,905	58,542
Machinery and Equipment | Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	3 years
Machinery and Equipment | Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	15 years
Furniture, fixtures and office equipment
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 2,976	2,976
Furniture, fixtures and office equipment | Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	5 years
Furniture, fixtures and office equipment | Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	10 years
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 8,646	8,246
Estimated Useful Life (Years)	3 years
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 37,412	$ 16,706

Depreciation Expense Related to

Depreciation Expense Related to Property and Equipment (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation Expense	$ 1,095	$ 727	$ 2,133	$ 1,326

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - Casper L L C $ in Millions	1 Months Ended
	Nov. 30, 2021 USD ($)
Property Plant And Equipment [Line Items]
Sale price	$ 102.3
Sale leaseback transaction, lease agreement period.	20 years
Sale leaseback transaction, date	November 2021

Goodwill and Other Intangible_3

Goodwill and Other Intangible Asset - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 1,931	$ 2,428
2023	100
2024	100
2025	100
2026	100
2027	100
Thereafter 2027	$ 600

Goodwill and Other Intangible_4

Goodwill and Other Intangible Asset - Summary of Other Intangible Asset (Detail) - Developed Technology - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Finite Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	15 years
Cost	$ 1,200	$ 1,200
Accumulated Amortization	(87)	(47)
Net Book Value	$ 1,113	$ 1,153

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Salary and related expenses	$ 12,140	$ 14,906
Discounts and allowances for commercial product sales	10,153	8,504
Accrued interest	6,267	2,201
Current portion of milestone rights liability	1,676	924
Deferred lease liability	944	1,304
Professional fees	818	1,136
Returns reserve for acquired product	633	1,013
Danbury facility buildout	93	846
Other	4,109	4,719
Accrued expenses and other current liabilities	$ 36,833	$ 35,553

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities (Parenthetical) (Detail) $ in Millions	Jun. 30, 2023 USD ($)
Accrued Expenses and Other Current Liabilities [Line Items]
Milestone Rights Payment	$ 5
Milestone rights liability to be paid	0.9
Short Term Milestone Right Liability	0.8
Accrued interest
Accrued Expenses and Other Current Liabilities [Line Items]
Milestone Rights Payment	$ 4.1

Borrowings - Summary of Carryin

Borrowings - Summary of Carrying Amount of Borrowings (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Senior convertible notes	$ 226,124	$ 225,397
Total debt — net carrying amount	274,431	273,490
Related Party
Debt Instrument [Line Items]
Mann Group convertible note	8,829	8,829
MidCap Credit Facility
Debt Instrument [Line Items]
Credit Facility	$ 39,478	$ 39,264

Borrowings - Schedule of Line o

Borrowings - Schedule of Line of Credit Facility Debt and Key Terms (Detail) - USD ($) $ / shares in Units, $ in Millions		6 Months Ended
		Jun. 30, 2023	Dec. 31, 2022	Mar. 04, 2021
Senior Convertible Notes
Debt Instrument [Line Items]
Amount Due		$ 230	$ 230
Annual interest rate		2.50%
Maturity date		2026-03
Conversion price		$ 5.21		$ 5.21
MidCap Credit Facility
Debt Instrument [Line Items]
Amount Due	[1]	$ 40	40
Maturity date	[1]	2025-08
SOFR | MidCap Credit Facility
Debt Instrument [Line Items]
Annual interest rate	[1]	6.25%
Interest rate floor	[1]	1%
Interest rate cap	[1]	8.25%
The Mann Group L L C | Convertible Promissory Note
Debt Instrument [Line Items]
Amount Due		$ 8.8	$ 8.8
Annual interest rate		2.50%
Maturity date		2025-12
Conversion price		$ 2.5
[1] In August 2022, the Company amended the MidCap credit facility and transitioned the benchmark interest rate from LIBOR to the Secured Overnight Financing Rate (“SOFR”).

Borrowings - Schedule of Maturi

Borrowings - Schedule of Maturities of Company's Borrowings (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
2023	$ 6,667
2024	20,000
2025	22,163
2026	230,000
Total principal payments	278,830
Unamortized discount	(521)
Debt issuance costs	(3,878)
Total debt — net carrying amount	$ 274,431	$ 273,490

Borrowings - Senior Convertible

Borrowings - Senior Convertible Notes - Additional Information (Detail)			1 Months Ended	6 Months Ended
	Apr. 22, 2021	Mar. 04, 2021 USD ($) d $ / shares	Aug. 31, 2019	Jun. 30, 2023 USD ($) d $ / shares	Dec. 31, 2022 USD ($) $ / shares	Mar. 31, 2021 USD ($)
Debt Instrument [Line Items]
Maturity date	Dec. 31, 2025		Nov. 03, 2024
Common stock, par value | $ / shares				$ 0.01	$ 0.01
Senior Convertible Notes
Debt Instrument [Line Items]
Principal amount				$ 230,000,000	$ 230,000,000
Maturity date				Mar. 01, 2026
Annual interest rate				2.50%
Common stock, par value | $ / shares				$ 0.01
Number of trading days | d		20		20
Consecutive trading days | d		30		30
Conversion price percentage		130%		130%
Principal amount per share | $ / shares		$ 1,000		$ 1,000
Measurement period percentage				98%
Conversion price | $ / shares		$ 5.21		$ 5.21
Initial conversion price of premium percentage		30%
No of convertible shares		191.8281
Redemption period start date		Mar. 06, 2024
Redemption price percentage		100%
Sinking fund		$ 0
Debt instrument redemption description				The Company may not redeem the Senior convertible notes prior to March 6, 2024. The Company may redeem for cash all or any portion of the Senior convertible notes, at its option, on or after March 6, 2024 and prior to the 36th scheduled trading day immediately preceding the maturity date, if the last reported sale price of common stock has been at least 130% of the conversion price for the Senior convertible notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Senior convertible notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company elects to redeem less than all of the outstanding Senior convertible notes, at least $75.0 million aggregate principal amount of Senior convertible notes must be outstanding and not subject to redemption as of the relevant redemption notice date. No sinking fund is provided for the Senior convertible notes.
Percentage of repurchase price		100%
Debt default, description				If certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries) occur, 100% of the principal of and accrued and unpaid interest on the Senior convertible notes will automatically become due and payable. If an event of default with respect to the Senior convertible notes, other than certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries), occurs and is continuing, the trustee, by notice to the Company, or the holders of at least 25% in principal amount of the outstanding Senior convertible notes by notice to the Company and the trustee, may, and the trustee at the request of such holders shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the Senior convertible notes to be due and payable. Notwithstanding the foregoing, the Indenture provides that, to the extent the Company so elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 365 days after the occurrence of such an event of default consist exclusively of the right to receive additional interest on the Senior convertible notes as set forth in the Indenture
Proceeds from offering after deducting initial purchasers discounts and commissions and estimated offering expenses payable		$ 222,700,000
Unamortized debt issuance cost				$ 3,900,000
Senior Convertible Notes | Minimum
Debt Instrument [Line Items]
Outstanding principal amount redeemed		$ 75,000,000
Senior Convertible Notes | Private Placement
Debt Instrument [Line Items]
Principal amount						$ 230,000,000

Borrowings - MidCap Credit Faci

Borrowings - MidCap Credit Facility - Additional Information (Detail)			1 Months Ended			6 Months Ended	12 Months Ended
		Apr. 22, 2021	Apr. 30, 2021 USD ($)	Dec. 31, 2020 Installment	Aug. 31, 2019 USD ($) Installment	Jun. 30, 2023 USD ($)	Dec. 31, 2020 USD ($)	Mar. 31, 2021 USD ($)
Debt Instrument [Line Items]
Maturity date		Dec. 31, 2025			Nov. 03, 2024
Debt instrument payment term description						Principal on each term loan advance under Tranche 1 and Tranche 2 are payable in 24 equal monthly installments beginning September 1, 2023, until paid in full on August 1, 2025.
Unamortized debt discount						$ 521,000
On or After April 23, 2023 Through Maturity Date
Debt Instrument [Line Items]
Early termination fees, percentage						1%
MidCap Credit Facility
Debt Instrument [Line Items]
Prepaid of borrowing			$ 10,000,000
Debt instrument minimum unrestricted cash and short-term investments					$ 90,000,000
Principal prepayment against outstanding term loans			10,000,000
Debt instrument, prepayment penalty			1,000,000
Unamortized debt discount						$ 200,000
Debt Instrument unamortized prepayment penalty.						$ 400,000
Interest on loans increased, percentage					2%
MidCap Credit Facility | SOFR
Debt Instrument [Line Items]
Interest rate floor	[1]					1%
Tranche 1
Debt Instrument [Line Items]
Maturity date					Aug. 01, 2025
Annual interest rate					8.25%
Debt payable number of equal monthly installments | Installment					24
Line of credit facility principal payment start date					Sep. 01, 2023
Tranche 1 | SOFR
Debt Instrument [Line Items]
Interest rate (LIBOR)					6.25%
Interest rate floor					1%
Tranche 1 | MidCap Credit Facility
Debt Instrument [Line Items]
Advance of borrowing					$ 40,000,000
Tranche 2
Debt Instrument [Line Items]
Maturity date				Aug. 01, 2025
Annual interest rate				8.25%			8.25%
Debt payable number of equal monthly installments | Installment				24
Line of credit facility principal payment start date				Sep. 01, 2023
Tranche 2 | SOFR
Debt Instrument [Line Items]
Interest rate (LIBOR)				6.25%
Interest rate floor				1%
Tranche 2 | MidCap Credit Facility
Debt Instrument [Line Items]
Advance of borrowing							$ 10,000,000
Tranche 3 | MidCap Credit Facility
Debt Instrument [Line Items]
Amount available under credit facility			$ 60,000,000			$ 60,000,000		$ 25,000,000
Debt instrument advance available date			Jun. 30, 2022
Debt instrument extended interest-only date			Sep. 01, 2023
Maturity date			Aug. 01, 2025
Debt instrument payment term description						The MidCap credit facility has been amended several times, including in April 2021 when the parties agreed to, among other things, (i) increase the amount available under the third advance from $25.0 million to $60.0 million and extend the date through which the third advance is available to June 30, 2022, (ii) amend the conditions to the third advance of $60.0 million being available to draw, including certain milestone conditions associated with Tyvaso DPI, (iii) remove the Company’s obligation to issue a warrant to purchase shares of the Company’s common stock upon drawing down the third advance, (iv) extend the interest-only period until September 1, 2023 and extend the maturity date until August 1, 2025, (v) amend the financial covenant relating to trailing 12 month minimum Afrezza net revenue, (vi) decrease the minimum cash covenant, (vii) decrease the interest rate on any amounts outstanding, now or in the future, under the MidCap credit facility, (viii) permit the Company to make certain acquisitions, subject to requirements, and (ix) permit the Company to make investments of up to an additional $9.0 million so long as the Company has $90.0 million or more of unrestricted cash and short-term investments following such investment.
Maximum value of additional investment limit			$ 9,000,000
Debt instrument minimum unrestricted cash and short-term investments			$ 90,000,000
[1] In August 2022, the Company amended the MidCap credit facility and transitioned the benchmark interest rate from LIBOR to the Secured Overnight Financing Rate (“SOFR”).

Borrowings - Mann Group Promiss

Borrowings - Mann Group Promissory Notes - Additional Information (Detail) $ / shares in Units, $ in Millions		1 Months Ended	6 Months Ended
	Apr. 22, 2021	Aug. 31, 2019 USD ($) $ / shares	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) shares	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Debt instrument payment term description			Principal on each term loan advance under Tranche 1 and Tranche 2 are payable in 24 equal monthly installments beginning September 1, 2023, until paid in full on August 1, 2025.
Maturity date	Dec. 31, 2025	Nov. 03, 2024
The Mann Group L L C | Convertible Promissory Note
Debt Instrument [Line Items]
Principal amount | $			$ 8.8		$ 8.8
Senior notes, effective interest rate			2.50%
Conversion price			$ 2.5
Debt issuance amount | $				$ 10
Capitalized interest into common stock | shares				4,000,000
Common stock issued to pay interest | shares			23,683	31,541
The Mann Group L L C | New Loan Arrangement | Convertible Promissory Note
Debt Instrument [Line Items]
No of convertible shares		400
Principal amount per share		$ 1,000
Conversion price		$ 2.50
The Mann Group L L C | New Loan Arrangement | Promissory Notes
Debt Instrument [Line Items]
Senior notes, effective interest rate	2.50%	7%
Debt instrument payment term description		quarterly
Debt instrument, date of first required interest payment		Oct. 01, 2019
The Mann Group L L C | Privately Negotiated Exchange Agreement | Loan Arrangement
Debt Instrument [Line Items]
Common stock price per share		$ 2.50
The Mann Group L L C | Privately Negotiated Exchange Agreement | Loan Arrangement | Convertible Promissory Note
Debt Instrument [Line Items]
Principal amount | $		$ 35

Borrowings - Schedule of Amorti

Borrowings - Schedule of Amortization of Premium and Accretion of Debt Issuance Costs (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Debt Disclosure [Abstract]
Amortization of debt discount	$ 108	$ 106	$ 214	$ 212
Amortization of debt issuance cost	$ 363	$ 363	$ 727	$ 726

Borrowings - Milestone Rights -

Borrowings - Milestone Rights - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Remaining milestone rights liability	$ 4,800	$ 4,800
Milestone liabilities	3,772	4,524
Milestone rights liability, current	1,700	1,700
Barings Global Milestone Rights
Debt Instrument [Line Items]
Milestone liabilities	$ 3,200	$ 3,200

Collaboration, Licensing and _3

Collaboration, Licensing and Other Arrangements - Schedule of Revenue from Collaborations and Services (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue from collaborations and services	$ 48,611	$ 18,894	$ 89,237	$ 30,886
Collaborations and services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue from collaborations and services	11,211	5,868	22,597	8,034
Collaborations and services | License and Distribution Agreement | Cipla Ltd
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue from collaborations and services	36	36	73	73
Collaborations and services | Co-Promotion Agreement | Vertice Pharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue from collaborations and services		325		325
Collaborations and services | Other
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue from collaborations and services		114		201
Collaborations and services | United Therapeutics Corporation | Commercial Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue from collaborations and services	10,933	4,695	22,097	5,879
Collaborations and services | United Therapeutics Corporation | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue from collaborations and services	$ 242	$ 698	$ 427	$ 1,556

Collaboration, Licensing and _4

Collaboration, Licensing and Other Arrangements - Summary of UT Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT	$ 48,611	$ 18,894	$ 89,237	$ 30,886
United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT	30,230	5,697	53,257	7,739
United Therapeutics Corporation | Commercial Supply Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT	10,933	4,695	22,097	5,879
United Therapeutics Corporation | License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT	242	698	427	1,556
United Therapeutics Corporation | Royalties Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT	$ 19,055	$ 304	$ 30,733	$ 304

Collaboration, Licensing and _5

Collaboration, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)		1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
		Dec. 31, 2022	May 31, 2018	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Feb. 28, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue - current		$ 1,733,000		$ 3,489,000		$ 3,489,000		$ 1,733,000
Deferred revenue - non-current		37,684,000		60,248,000		60,248,000		37,684,000
Total revenue from UT				48,611,000	$ 18,894,000	89,237,000	$ 30,886,000
Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				11,211,000	5,868,000	22,597,000	8,034,000
AFREZZA product sales
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				18,345,000	12,722,000	35,907,000	22,548,000
United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				30,230,000	5,697,000	53,257,000	7,739,000
United Therapeutics Corporation | Manufacturing Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Funding for development of alternative manufacturing processes		2,300,000
United Therapeutics Corporation | Commercialization and Continuous Improvement Activities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Funding for capital improvements		39,500,000
Thirona Bio, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Minimum amount to expended									$ 1,100,000
Collaboration and License Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows	[1]	722,300,000						722,300,000
Deferred revenue		37,900,000		62,300,000		62,300,000		37,900,000
Deferred revenue - current		1,600,000		3,300,000		3,300,000		1,600,000
Deferred revenue - non-current		36,300,000		59,000,000		59,000,000		36,300,000
Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows		722,300,000						722,300,000
Allocated transaction price		220,800,000
Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services | Transaction Price For The Contractual Obligations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows		120,000,000						120,000,000
Collaboration and License Agreement | United Therapeutics Corporation | Next-Gen R&D Services | Transaction Price For The Performance Obligations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows		$ 602,300,000						602,300,000
Commercial Supply Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				10,933,000	4,695,000	22,097,000	5,879,000
Supply and Distribution Agreement | AFREZZA product sales | Biomm
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT						0		$ 0
License and Distribution Agreement | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue				1,400,000		1,400,000
Deferred revenue - current				100,000		100,000
Deferred revenue - non-current				1,300,000		1,300,000
Marketing and distribution agreement date			2018-05
License and Distribution Agreement | Collaborations and services | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				$ 36,000	$ 36,000	$ 73,000	$ 73,000
[1] The total anticipated cash flow includes a transaction price of $ 120.0 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $ 602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA.

Collaboration, Licensing and _6

Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Detail) - Collaboration and License Agreement - United Therapeutics Corporation $ in Millions	1 Months Ended
	Dec. 31, 2022 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows	$ 722.3	[1]
R&D Services and License | Over Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Progress Measure	Ratably
Recognition Period	Aug 2021 - Oct 2021
Next-Gen R&D Services | Over Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Anticipated Revenue Allocation	$ 10
Progress Measure	Input
Recognition Period	% of completion of costs
Manufacturing Services and Product Sales | Point In Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Anticipated Revenue Allocation	$ 712.3	[2]
Recognition Period	Transfer of control	[2]
[1] The total anticipated cash flow includes a transaction price of $ 120.0 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $ 602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA. The Manufacturing Services performance obligation will be recognized as control of manufactured products is transferred to UT. The modification did not result in a cumulative catch-up adjustment as a result of the revenue being deferred for the performance obligations that were affected by the modification. The allocation of the transaction price for the Manufacturing Services includes a material right related to the Company’s estimated production of product in the amount of $ 220.8 million. The Company will sell product to UT under individual purchase orders, which represent distinct performance obligations. The ultimate cash flows may vary as manufacturing purchase orders are received.

Collaboration, Licensing and _7

Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Parenthetical) (Details) - United Therapeutics Corporation - Collaboration and License Agreement $ in Millions	1 Months Ended
	Dec. 31, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total anticipated cash flows	$ 722.3	[1]
Manufacturing Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total anticipated cash flows	722.3
Allocated transaction price	220.8
Manufacturing Services | Transaction Price For The Contractual Obligations
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total anticipated cash flows	120
Next-Gen R&D Services | Transaction Price For The Performance Obligations
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total anticipated cash flows	$ 602.3
[1] The total anticipated cash flow includes a transaction price of $ 120.0 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $ 602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA.

Collaboration, Licensing and _8

Collaboration, Licensing and Other Arrangements - Additional Information (Detail 1) - License and Distribution Agreement - Cipla Ltd - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2018-06-01 $ in Millions	May 31, 2018 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Anticipated revenue allocation	$ 2.2
Deferred revenue recognition period	15 years

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Fair Value of Financial Instruments (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Carrying Amount | MidCap Credit Facility
Financial liabilities:
Total financial liabilities fair value	$ 39,478	$ 39,264
Carrying Amount | Senior Convertible Notes
Financial liabilities:
Total financial liabilities fair value	226,124	225,397
Carrying Amount | Mann Group Convertible Note
Financial liabilities:
Total financial liabilities fair value	8,829	8,829
Carrying Amount | Milestone Rights Liability
Financial liabilities:
Total financial liabilities fair value	4,838	4,838
Carrying Amount | Contingent Milestone Liability
Financial liabilities:
Total financial liabilities fair value	610	610
Carrying Amount | Financing Liability
Financial liabilities:
Total financial liabilities fair value	104,081	104,077
Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3 | MidCap Credit Facility
Financial liabilities:
Total financial liabilities fair value	41,721	41,070
Estimate of Fair Value Measurement | Senior Convertible Notes | Fair Value, Inputs, Level 3
Financial liabilities:
Total financial liabilities fair value	241,904	253,864
Estimate of Fair Value Measurement | Mann Group Convertible Note | Fair Value, Inputs, Level 3
Financial liabilities:
Total financial liabilities fair value	16,316	20,836
Estimate of Fair Value Measurement | Milestone Rights Liability | Fair Value, Inputs, Level 3
Financial liabilities:
Total financial liabilities fair value	11,800	12,600
Estimate of Fair Value Measurement | Contingent Milestone Liability | Fair Value, Inputs, Level 3
Financial liabilities:
Total financial liabilities fair value	610	960
Estimate of Fair Value Measurement | Financing Liability | Fair Value, Inputs, Level 3
Financial liabilities:
Total financial liabilities fair value	$ 103,229	$ 103,239

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Fair Value of Financial Instruments (Parenthetical) (Detail) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
MidCap Credit Facility
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of hypothetical yield	12	12
Note payable, percentage of interest rate increases (decreases)	2%	2%
MidCap Credit Facility | Minimum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 40.9	$ 40
MidCap Credit Facility | Maximum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 42.6	$ 42.4
Mann Group Convertible Note
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of hypothetical yield	13	13
Note payable, percentage of interest rate increases (decreases)	2%	2%
Mann Group Convertible Note | Volatility
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of volatility	72.3	77.8
Mann Group Convertible Note | Minimum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 16	$ 20.5
Mann Group Convertible Note | Maximum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 16.6	$ 21.2
Senior Convertible Notes
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of hypothetical yield	11	13
Note payable, percentage of interest rate increases (decreases)	2%	2%
Senior Convertible Notes | Volatility
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of volatility	72.9	75.8
Senior Convertible Notes | Minimum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 233.4	$ 245
Senior Convertible Notes | Maximum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 250.9	$ 263.4
Financing Liability
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of hypothetical yield	10	10

Common and Preferred Stock - Ad

Common and Preferred Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	Feb. 28, 2018	Jun. 30, 2023	Jun. 30, 2022	May 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Common stock, shares authorized		800,000,000		400,000,000	400,000,000
Common stock, par value		$ 0.01			$ 0.01
Undesignated preferred stock, shares authorized		10,000,000			10,000,000
Undesignated preferred stock, par value		$ 0.01			$ 0.01
Common stock, shares issued		268,235,145			263,793,305
Common stock, shares outstanding		268,235,145			263,793,305
Preferred stock, shares outstanding		0			0
Proceeds from market price stock purchase plan		$ 1,075	$ 684
Market Price Stock Purchase Plan ("MPSPP")
Class of Stock [Line Items]
Proceeds from market price stock purchase plan		$ 200	$ 700
Market price stock purchase plan		36,004	252,176
Convertible Promissory Note | The Mann Group L L C
Class of Stock [Line Items]
Debt issuance amount			$ 10,000
Capitalized interest into common stock			4,000,000
Common stock issued to pay interest		23,683	31,541
Controlled Equity Offering Sales Agreement | Cantor Fitzgerald | Common Stock | Maximum
Class of Stock [Line Items]
Amount of net proceeds from issuance of securities	$ 50,000
At Market Issuance Sales Agreement | Cantor Fitzgerald | Common Stock
Class of Stock [Line Items]
Amount of net proceeds from issuance of securities		$ 2,800
Number of shares sold during the period		631,383	0
At Market Issuance Sales Agreement | Cantor Fitzgerald | Common Stock | Weighted Average
Class of Stock [Line Items]
Exchange price per share		$ 4.4

Earnings Per Common Share ("E_3

Earnings Per Common Share ("EPS") - Components of Basic and Diluted EPS Computations (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
EPS — basic and diluted:
Net loss (numerator)	$ (5,265)	$ (9,795)	$ (29,023)	$ (25,998)	$ (15,060)	$ (55,021)
Weighted average common shares (denominator), Basic	265,626		253,644		264,802	252,775
Weighted average common shares (denominator), Diluted	265,626		253,644		264,802	252,775
Net loss per share, Basic	$ (0.02)		$ (0.11)		$ (0.06)	$ (0.22)
Net loss per share, Diluted	$ (0.02)		$ (0.11)		$ (0.06)	$ (0.22)

Earnings Per Common Share ("E_4

Earnings Per Common Share ("EPS") - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Detail) - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	73,130,822	73,340,468
Senior Convertible Notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	44,120,463	44,120,463
RSUs and Market RSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	16,951,734	15,848,183
Common Stock Options and PNQs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	8,688,625	9,766,028
Mann Group Convertible Notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	3,370,000	3,370,000
Employee Stock Purchase Plan
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share		235,794

Earnings Per Common Share ("E_5

Earnings Per Common Share ("EPS") - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Parenthetical) (Detail) - RSU	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Share delivery percentage in accordance with valuation assessment obtained		162%	0%
Forecast
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Share delivery percentage in accordance with valuation assessment obtained	100%

Stock-Based Compensation Expe_3

Stock-Based Compensation Expense - Additional Information (Detail) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2023	May 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of common stock under the employee stock purchase plan	$ 923,000		$ 740,000
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of common stock under the employee stock purchase plan	$ 3,000		$ 2,000
Issuance of common stock under the employee stock purchase plan (in shares)	266,000		233,000
ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity incentive plan, number of shares available for grant increased by shares					3,000,000
Common stock available for issuance	3,100,000			3,100,000
Employees Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of common stock under the employee stock purchase plan				$ 25,000
Issuance of common stock under the employee stock purchase plan (in shares)				5,000
Employees Awards | ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Discount on purchase price percentage of fair market value				85%
Options and PNQs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense related to options	$ 200,000			$ 200,000
Unrecognized compensation expense, weighted average period for recognition				2 years 11 months 4 days
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units weighted average grant date fair value	$ 4.56	$ 4.16
Unrecognized compensation expense, weighted average period for recognition				2 years 8 months 23 days
Unrecognized compensation expense related to non-option	$ 24,000,000			$ 24,000,000
RSUs | Employees Awards | Share-Based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years	3 years
Restricted stock units grant date fair value	2,598,971	91,900
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25%
RSUs | Employees Awards | Share-Based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	3 years	2 years
Restricted stock units grant date fair value	61,750	42,000
RSUs | Employees Awards | Share-Based Payment Arrangement, Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		4 years
Restricted stock units grant date fair value		46,005
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25%
Market RSU's
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense, weighted average period for recognition				2 years 25 days
Unrecognized compensation expense related to non-option	$ 20,900,000			$ 20,900,000
Market RSU's | Employees Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units weighted average grant date fair value	$ 9.4
Market RSU's | Employees Awards | Share-Based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	0%
Market RSU's | Employees Awards | Share-Based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50%
Market RSU's | Employees Awards | Share-Based Payment Arrangement, Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	100%
2018 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity incentive plan, number of shares available for grant increased by shares					25,000,000

Stock-Based Compensation Expe_4

Stock-Based Compensation Expense - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted awards	4,425,625	179,905	4,605,530
Employees Awards | RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted awards	2,660,721	179,905	2,840,626
Employees Awards | Market RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted awards	1,445,000		1,445,000
Non-employee Directors Awards | RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted awards	319,904		319,904

Stock-Based Compensation Expe_5

Stock-Based Compensation Expense - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Parenthetical) (Details) - $ / shares	3 Months Ended
	Jun. 30, 2023	Mar. 31, 2023
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units weighted average grant date fair value	$ 4.56	$ 4.16
Employees Awards | RSUs | Share-Based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units grant date fair value	2,598,971	91,900
Vesting period	4 years	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25%
Employees Awards | RSUs | Share-Based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units grant date fair value	61,750	42,000
Vesting period	3 years	2 years
Employees Awards | RSUs | Index Target 50th Percentile
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units grant date fair value		46,005
Vesting period		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25%
Employees Awards | Market RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units weighted average grant date fair value	$ 9.4
Vesting date	Jul. 15, 2026
Employees Awards | Market RSUs | Share-Based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	0%
Employees Awards | Market RSUs | Share-Based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50%
Employees Awards | Market RSUs | Index Target 50th Percentile
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	100%
Employees Awards | Market RSUs | Index Target 75th Percentile
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	200%
Employees Awards | Market RSUs | Index Target 90th Percentile or Higher
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	300%
Non-employee Directors Awards | RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units weighted average grant date fair value	$ 4.55

Stock-Based Compensation Expe_6

Stock-Based Compensation Expense - Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total	$ 5,580	$ 4,422	$ 9,235	$ 7,228
RSUs and Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total	5,404	4,239	8,882	6,883
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total	$ 176	$ 183	$ 353	$ 345

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended		6 Months Ended
	Jun. 30, 2022	Nov. 30, 2021	Nov. 30, 2017	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Jul. 01, 2013
Commitments And Contingencies [Line Items]
Operating lease costs				$ 410,000	$ 341,000	$ 831,000	$ 629,000
Financing liability				104,100,000		104,100,000		$ 104,100,000
Financing liability, long term				94,395,000		94,395,000		94,512,000
Financing liability, short term				9,686,000		$ 9,686,000		$ 9,565,000
Supply Agreement expiration period						Dec. 31, 2027
Supply Agreement renewal period						2 years
Equipment | V-Go
Commitments And Contingencies [Line Items]
Embedded lease cost per month	$ 14,370
Master Lease Agreement with Enterprise | Vehicle Leases
Commitments And Contingencies [Line Items]
Operating lease rent expenses						$ 100,000
Marlborough Lease | Buildings
Commitments And Contingencies [Line Items]
Operating lease rent expenses	$ 28,895
Percentage of annual increase in lease payment	3%
Casper L L C
Commitments And Contingencies [Line Items]
Sale price		$ 102,300,000
Lease initial term		20 years
Lease renewal option		4 years
Lease renewal options		renewal options of five years
Lessee,option to extend [true false]		true
Operating lease costs		$ 9,500,000
Lease, description		The total annual rent under the Lease starts at approximately $9.5 million per year, subject to a 50% rent abatement during the first year of the Lease, and will increase annually by (i) 2.5% in the second through fifth year of the Lease and (ii) 3% in the sixth and each subsequent year of the Lease, including any renewal term.
Security deposit		$ 2,000,000
Lease repurchase description		the Company has four options to repurchase the Property, in 2026, 2031, 2036 and 2041, for the greater of (i) $102.3 million and (ii) the fair market value of the Property.
Minimum | Casper L L C
Commitments And Contingencies [Line Items]
Lease repurchase, amount		$ 102,300,000
Deerfield | Milestone Rights Liability
Commitments And Contingencies [Line Items]
Contingent liability remain payable				$ 60,000,000		$ 60,000,000			$ 60,000,000
Deerfield | Milestone Rights Liability | Maximum
Commitments And Contingencies [Line Items]
Contingent liability for milestone payments									$ 90,000,000
Russell Ranch Road II LLC | Office Lease
Commitments And Contingencies [Line Items]
Operating lease rent expenses			$ 79,543
Percentage of annual increase in lease payment			3%
Description of right to extension of lease term						The Company has no further right to extend the lease term beyond July 31, 2028.
Russell Ranch Road II LLC | Maximum | Office Lease
Commitments And Contingencies [Line Items]
Reimbursement for tenant improvements			$ 900,000
Additional base rent concession			$ 700,000

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Financing Liability Lease Term and Discount Rate (Detail)	Jun. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Weighted average remaining lease term (in years)	18 years 3 months 18 days	18 years 9 months 18 days
Weighted average discount rate	9%	9%

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Financing Liability Costs (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Interest expense on financing liability	$ 2,449	$ 2,443	$ 4,873	$ 4,814

Commitments and Contingencies_4

Commitments and Contingencies - Schedule of Remaining Financing Liability Payments (Detail) $ in Thousands	Jun. 30, 2023 USD ($)
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
2023	$ 4,906
2024	10,018
2025	10,269
2026	10,533
2027	10,849
Thereafter	188,453
Total	235,028
Interest payments	(128,166)
Debt issuance costs	(2,781)
Total financing liability	$ 104,081

Commitments and Contingencies_5

Commitments and Contingencies - Remaining Purchase Requirements (Detail) € in Millions	Jun. 30, 2023 EUR (€)
Purchase Obligation, Fiscal Year Maturity [Abstract]
2023	€ 4.8
2024	14.6
2025	15.5
2026	19.4
2027	€ 9.2

Commitments and Contingencies_6

Commitments and Contingencies - Schedule of Lease Term and Discount Rate (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	May 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Operating lease, right-of-use asset	$ 5,329	$ 6,714
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Operating lease liability-current	$ 944	$ 1,304
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued expenses and other current liabilities	Accrued expenses and other current liabilities
Operating lease liability	$ 4,646	$ 5,343
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Operating lease liability	Operating lease liability
Total	$ 5,590	$ 6,647
Weighted average remaining lease term (in years)	4 years 1 month 6 days	4 years 7 months 6 days
Incremental borrowing rate	7.30%	7.30%	7.25%

Commitments and Contingencies_7

Commitments and Contingencies - Summary of Lease Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Operating lease costs	$ 410	$ 341	$ 831	$ 629
Variable lease costs	13	73	49	159
Cash paid	$ 234	$ 446	$ 557	$ 887

Commitments and Contingencies_8

Commitments and Contingencies - Schedule of Future Minimum Office And Vehicle Lease Payments (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Commitments And Contingencies [Line Items]
Operating lease, liability	$ 5,590	$ 6,647
office and vehicle
Commitments And Contingencies [Line Items]
Year 1	441
Year 2	1,496
Year 3	1,861
Year 4	1,140
Year 5	1,072
Thereafter	643
Total	6,653
Interest expense	(1,063)
Operating lease, liability	$ 5,590

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2023 USD ($)
Income Tax Disclosure [Abstract]
Unrecognized income tax interest and penalties	$ 0